vaccine-preventable pre-course general subject free possible current such assert subsequent additional digital re-hosted educational non-commercial computer-extracted Computer-extracted such unusual odd Original 2021-11-05 PRE-COURSE ixti other preventive acellular supplementary fourth fifth supplementary supplementary older immune viral comprehensive universal human supplementary human permanent 663-4,669-75 Yellow Japanese general separate different live yellow short other least live same simultaneous eligible pneumococcal general live-virus different same live-virus 4-6 subsequent live other necessary less True live least live-virus eligible asymptomatic symptomatic HIV-infected pregnant live pregnant last first pregnant current antimicrobial low-grade mild skin public permanent public private absolute 6-10 4-6 1-2 6-18 21-2 6-18 ral acellular ut available active passive non-infectious systemic subcutaneous most upper acceptable same same different intramuscular 25-gauge 5/8-inch long maximum adverse primary necessary / 205-214 219-227 new available immune different routine human contraindi- scientific active passive public clinical safe effective partial conse- asymptomatic such common trivial severe life-threatening scientific infectious specific other relative antigenic such antibody- human active passive live infectious complex live modified bacterial sterile human large available subcutaneous intradermal viral intramuscular subcutaneous pneumococcal specific lower same acetone-killed dried intramuscular certain immunodeficient passive other infectious similar suitable intravenous infectious high specific varicella- infectious specific passive inclusive active passive other immune temporary passive human specific active many specific same infectious different active various same familiar small other cell-culture-derived bacterial viral final sensitive immunologic natural such Table unneces- sary local systemic optimal deep local little local neural older volar severe intramuscular anterolateral upper most anterolateral largest preferred individual intramuscular sciatic immunoge- subcutaneous deep large multiple necessary large central upper disposable intramuscular sufficient subcutaneous 20- 22-gauge needle small 25-gauge 5/8-inch-long subcutaneous intradermal 25-gauge needle recom- new separate Disposable puncture-proof vaccine different theoretical experimental clinical smaller such intradermal larger hazardous excessive local smaller total multiple smaller full serologic clinical such Table age-specific age-specific maternal general youngest acceptable more adequate periodic multiple final necessary inter-rupted extra less recommended primary local certain Such Good such extensive clinical scientific certain same active normal * high 6-wk 2-mo additional optional high primary polysaccharide 4-6 old single-antigen different same useful specific consistent current second third 4-8 least fewer least last previous simultaneous acceptable last routine 2-dose first first first second first routine 2-dose acceptable routine single least polysaccharide available acceptable high available seventh same same same helpful imminent several infectious foreign Simultaneous general separate local possible separate Simultaneous pneumococcal whole-virus influ- satisfactory adverse pneumococcal satisfactory general simultaneous impaired similar individual different medical equivalent significant adverse oral different early appropriate mos-5 additional optional high 6-12 4-6 14-16 first old seventh single available acceptable unavailable high second single least initial fifth second third 4-8 necessary fourth third fourth same simultaneous eligible acceptable other health-care simultaneous previous yellow safe efficacious yellow short other possible yellow least necessary 3-week yellow environmental hygienic other yellow general different inactivated live theoretical possible live-virus same least Table Live-virus same live-virus 4-6 necessary imminent early individual 6-12 seventh prior primary medical higher general medical deleterious single vaccine-induced specific yellow specific other antibody-containing general susceptible other last possible necessary live-virus 1-2 live-virus subsequent least serologic general inactivated immune immediate long-lasting different allergic local systemic responsible common yellow able anaphylactic reasonable yellow extreme anaphylactic severe live minimum live 4-wk minimum simulta- possible local systemic separate yellow least yellow other optimal severe hypersensitive such individual skin anaphylactic Most neomycin delayed-type cell-mediated immune such local systemic such difficult specific rare urticarial anaphylactic such appropriate live immune symptomatic large compli- live attenuated-virus immune general live other protective other such other least live-virus Short-term dose systemic topical nasal long-term alternate-day low different unavoidable different Nonsimultaneous live-virus oral yellow moderate short-acting systemic intra-articular immunosuppressive usual live-virus special such asymptomatic necessary HIV-infected present harmful asymptomatic theoretical symptomatic severe symptomatic asymptomatic symptomatic serious unusual adverse current recent severe minor such mild upper-respiratory low-grade contraindica- medical important severe febrile adverse Routine physical good severe appropriate theoretical likely pregnant live yellow pregnant substantial natural routine HIV-infected seventh second third reasonable theoretical susceptible pregnant first pregnant pregnant last first unimmunized primary possible last Eligible three-dose necessary pregnant susceptible passive available American certain contrain- previous soreness immediate acute low-grade mild diarrheal antimicrobial appropriate usual other infectious good other antibiotic anaphylactic available sudden unrelated safe effective minor local severe such impossible cause-and-effect untoward temporal complete informa- other health-care permanent certain adverse further adverse separate appropriate public federal local appropriate local Reportable private responsible understandable public similar private public private available current other similar private best vaccine-preventable important good intensive appropriate available health-care primary old medical pneumococcal serious pneumococcal annual possible susceptible different necessary child-care vaccine-preventable such appropriate institutional such child-care primary appropriate due health-care Such health-care at-risk increased toxoid important parental patient permanent immuni- many new health-care permanent medical permanent health-care private public federal local new permanent vaccine-preventable such adverse medical general Official Manufacturer-provided product-specific weekly special specific available available national specific foreign international communicable specific available individual American available American most manual infectious up-to-date other available healthy available American important available American many local technical other educational technical preventable different supplementary state- immune oral yellow hypersen- sitive asthmatic supplementary 36:281-2 permanent adverse Other primary neonatal young young other central-nervous-system Other supplementary personal new epidemio- available immunobiologic appropriate new possible serious neurologic other close recent recommen- late major common More fatal highest young most cutaneous single cutaneous notifiable fatal rare high appropriate apparent Most unvaccinated vaccinated recent many Limited 18-39 > protective 4-7 toxigenic nontoxigenic severe fatal noncutaneous other cutaneous pseudomembranous distinctive other bacterial certain American least nose national widespread older complete recent many undertaken 18-39 > protective 4-7 unvaccinated unknown uncertain medical less acute medical other such medical such Neonatal unhygienic nated transplacental maternal neonatal neonatal 1985-1989 ubiquitous primary subsequent necessary effective protective major notifiable highest widespread standardized late substantial annual annual annual pertussis-associated clear true true many unrecognized unreported diagnostic unavailable difficult direct-fluorescent-antibody nasopha- low variable different available experimental uniform widespread 1980-1989 highest striking true more complete clear communicable severe young 1980-1989 high several population-based 20-22 substantial primary essential older upper-respiratory-tract classic Older important important vaccinated young several epidemiologic 24-28 formaldehyde respective different adverse previous smaller standard intracerebral protective single various available aluminum-salt-adsorbed available nonabsorbed equivalent available 6.7-12.5 single human protective 2-10 special acellular adverse several least bacterial clinical filamentous 69-kiloDalton outer-membrane common adverse current immunogenic 29-36 clinical equivalent whole-cell single-dose adsorbed frequent local 517-335-8120 old older 4-8 first dose 4-8 second dose 6-12 third dose old elementary necessary fourth primary fourth last dose due third dose 6-12 second primary old seventh routine 4-to 8-week weeks-2 old possible fourth 6-12 third adequate integral routine adverse seventh primary second 4-8 first third dose 6-12 higher common younger primary subsequent recommended old seventh primary fourth fifth elementary necessary fourth primary fourth next frequent adverse old old old Special first primary age-United 4-8 first dose * 6-12 last dose first 4-to 8-week fourth 6-12 similar additional 4-8 third dose 6-12 further third dose 6-12 second primary fourth fifth elementary necessary fourth primary fourth major possible acellular active primary typical clinical such other certain neonatal pregnant unhygienic 4-8 last Pregnant similar complete teratogenic protective least > health-care uncertain complete primary continued adsorbed fewer total seventh more adverse less adequate medical primary common palpable adsorbed several 6-10/million such more common self-limited symptomatic useful febrile-convulsion-prone due new other serious such systemic high inconsolable > hypotonic-hyporesponsive short-lived Other more severe such prolonged rare temporal local higher other mild-to-moderate systemic frequent 41-43 possible neurologic present earliest serious such inevitable difficult serious acute manifest first specific clinical pathological inconsolable hypotonic-hyporesponsive difficult normal rare large serious neurologic 1976-1979 27,45-47 large serious neurologic young 2-36 infantile separate attributable neurologic age-matched significant serious acute attributable neurologic least neurologic normal subsequent neurologic permanent attributable wide small valid permanent neurologic Preliminary 10-year follow-up original permanent available same initial neurologic serious neurologic permanent neurologic 1974-1983 1974-1984 56-58 additional few definitive original recent neurologic serious individual rare other permanent such rare similar British British 49-54 other acute febrile individual serious neurologic permanent impossible clinical permanent several simple unrecognized underlying neurological developmental manifest short-lived severe mental developmental apparent several other systemic inevitable first pyrogenic severe early other succumb sudden many temporal rigorous unusual 13-month 12-year older other unrecognized independent several larger past 28,63-65 unexpected responsible other more such infantile progressive degenerative central- nervous-system scientific fewer socioeconomic young such likely such 4-28 identical non-specific unrelated immediate anaphylactic substantial such likely specific true further papular petechial urticarial appear antigen-antibody little due other such viral unlikely subsequent hemolytic thrombocytopenic new adverse 1-800-822-7967 other health-care permanent certain adverse full specific adverse severe adverse such hypotonic-hyporesponsive lower local full lower second third small clinical low reliable other clinical Other current lower high full current reduced-volume vaccine-related adverse unknown unrelated vaccina- simultaneous oral similar acceptable simultaneous previous special simultaneous current recent severe febrile sufficient such mild upper- with-out low-grade medical appropriate important severe short adverse Routine physical good severe precautionary circum- next adverse previous chronological greater physiologic 2-week intra-articular immunosuppressive available immunosuppressive reasonable Special available rare encephalopathy permanent central- certain nonencephalitic severe subsequent valid current better temporal further immediate anaphylactic such such responsible such specific severe immediate anaphylactic due identifiable shock-like hypotonic-hyporesponsive inconsolable major unresponsiveness few subsequent desirable necessary Such neurologic temporal subsequent previous such high possible due identifiable Such subsequent such febrile shock-like hypotonic-hyporesponsive uncommon permanent neurolog- ical inconsolable > unpleasant long-term other greater first following persistent subsequent substantial local other DTP-associated high hypotonic-hyporesponsive pro- Short-lived irrespective normal subsequent abnormal further certain subsequent second desirable neurologic appropriate young possible potential neurologic neurologic more prolonged most neurologic young neurological un- progressive progres- sive other therapeutic preventive important other Such important custodial special greater symptomatic neurologic intracerebral other neurologic individual current local low previous young unrelated current previous prudent neurologic other further complete neurologic next special other first first other first possible other first neurologic stable stable neurologic stable neuro- logic well-controlled single such neurologic certain such neonatal hypocalcemic young other central nervous other central nervous severe previous anaphylactic previous intradermal useful anaphylactic previous nonreactive full adverse nonspecific skin-test undiluted common inconsequential cutaneous hypersen- prior high clean minor toxoid-containing primary toxoid clean minor teratogenic second reasonable theoretical such health-care certain acute low-grade mild healthy antimicrobial infectious appropriate usual chronological adverse secondary additional close culture- secondary Such other habitual oral prompt antimicrobial antimicrobial negative prior antimicrobial other old old 7- 10-day oral effective possible multi-day oral antimicrobial secondary follow-up antimicrobial additional 10-day oral other close unknown immediate toxoid- primary primary previous available passive unvaccinated impossible allergic prophylactic small unvaccinated additional antimicrobial 5,000-10,000 appropriate different unlikely immune simultaneous helpful protective Such helpful antimicrobial cutaneous nontoxigenic toxigenic cutaneous 404-639-2888 cutaneous due nontoxigenic necessary practical useful proper important active primary primary unknown uncertain previous previous military least most military primary primary passive complete primary toxoid long-lasting complete primary boosters-even other appropriate least preferred active large susceptible acute such susceptible routine such potential primary follow-up passive animal few adverse prophylactic routine other limited old fourth last last frequent average separate separate possible oral trimethoprim-sulfamethoxazole trimethoprim sulfamethoxazole clinical effective clinical paroxysmal trimethoprim-sulfamethoxazole other clinical other close four-dose minimal primary available Diphtheria-pertussis-tetanus commercial 63:256-60 sudden 101:419-21 bibliographic cerebral triple 1959-1965 4:320-3 selective 4:371-404 small 44:1537-45 54:325-47 mathematical cutaneous older 10-year 17:229-45 active 67:380-92 16:939-73 toxoid 198:1030-1 antenatal effective 61:159-65 202:17-9 mathematical 1965-1966 clinical 280:569-74 neonatal pregnant 32:683-97 older 280:575-81 active 67:380-92 active 2:95-6 61:224-30 2:24-7 British whooping-cough 1:1463-71 British final 2:27-8 whooping cough vaccina- joint 1977:1-33 small 4:1-24 young 132:371-3 whooping 1:1180-2 59:162-5 low large 282:23-6 leukocytosis-promoting filamentous 31:1223-31 other preventive 34:405-14,419-26 antipyretics-supplementary 36:281-2 1971-81 elderly urban elderly 108:145-9 inner-city Tetanus-United 39:37-41 14:573-9 309:636-40 epidemiological 222:333-61 comparative 14:1-78 Pertussis-diagnostic 27:752-7 6:145-51 public 58:661-76 immunized 115:686-93 whooping 1:117-9 59:162-5 161:473-9 251:3109-13 further 61:429-37 4:1-24 whooping neurological young 81:939-84 acellular pertussis-component whole-cell pertussis-component 18-month-old 140:872-6 immune adverse conventional acellular 140:867-71 acellular young 141:949-53 Acellular acellular whole-cell 18- 24-month old 6:352-63 acellular clinical acellular 157:731-7 acellular whole-cell pertussis-component 4- 6-year-old 144:41-5 acellular pertussis-component diphtheria- whole-cell pertussis-component 17- 24-month-old 69-kilodalton 117:46-51 205-14,219-27 oral 63:1151-69 102:14-8 hypotonic-hyporesponsive diphtheria-tetanus-pertusssis follow-up 789-94 adverse adverse 68:650-60 DTP-associated prior serious acute neurological 282:1595-9 61:98-9 neurological further British 145-55 1:1031-4 central nervous 29:458-60 Canadian immuni- 1989:78-83 British infectious 1990:20-7 British 1989:207-10 10-year abstract 7-year diphtheria-tetanus- 263:1641-5 neurologic retrospective 113:801-5 neurological early whooping Danish 52:134-7 sudden sudden sudden extensive epidemiological 18:121-6 preliminary 107:175-9 115:527-31 diphtheria-tetanus toxoids-pertussis 6:876-7 vaccine-specific 1009-12 System-United 39:730-3 permanent adverse serologic Half-dose British 2:454-62 whooping measles-mumps-rubella older 11:73-84 immunosuppressed cutaneous toxoid 57:135-7 intellectual 1085-8 adverse diphtheria-pertussis-tetanus toxoids-polio 6:721-5 prophylactic 159-66 current 4:614-9 high 157:434-40 clinical 6:458-61 community- household-acquired large-scale central 157:1134-41 secondary / RR-1 1-10 third seventh young personal Simultaneous ..... supplementary such fourth fifth initial three-dose least other fourth fifth current general primary late inactivated whole bacterial effective due clear overall high available safe adverse local other mild such febrile hypotonic- hyporesponsive general high likely initial acellular routine limited clinical several antigenic additional various many multinational bacterial filamentous 69-kilodalton least fimbriae Several various acellular other general likely common adverse current whole-cell 10-19 acellular Japanese placebo-controlled clinical similar ug/dose acellular first 5-11 second 8-12 culture-confirmed higher culture-confirmed severe classic culture-confirmed direct compari- available acellular least equivalent whole-cell 21-23 effective responsible invasive uncertain acellular such several acellular clinical acellular higher many low personal acellular clinical equivalent whole-cell initial three-dose alternative available relative protective primary several clinical whole-cell fourth acellular sucrose acellular acellular 27-29 Clinical relative initial infant three-dose fourth fifth similar Clinical retrospective 7-30 unvaccinated clinical atypical pertussis-occurred additional unvaccinated < smaller similar similar other common systemic whole-cell general local common systemic one-fourth comparable immunologic whole-cell fourth 17-24 fifth > 4-fold 17-24 ACEL-IMUNE > 4-fold 4-6 ACEL-IMUNE whole-cell speci- fourth fifth first primary fourth 15-18 adequate adminis- early whole-cell fourth fifth available local other common systemic whole-cell single-dose third whole-cell 15-18 necessary least third whole-cell fourth integral primary 15-16 available routine simultaneous oral 15-18 seventh prior whole-cell adverse chil- fourth fifth 4-6 unpublished fourth whole-cell elementary available necessary fourth fourth young personal young previous immediate such such due moderate high fourth other central nervous younger whole-cell additional first major possible other acellular complete general systemic such whole-cell common self-limited symptomatic hypotonic-hyporesponsive 4-8 first 4-8 second third dose elementary necessary fourth primary fourth last dose due third dose second primary whole-cell fourth available Tetanus-diphtheria whole-cell similar severe such prolonged rare serious adverse such febrile common simultaneous whole-cell simultaneous acceptable simultaneous acceptable simultaneous previous special simultaneous fourth fifth seventh initial three-dose further same temporal subsequent anaphylactic severe central nervous major unresponsiveness few following temporal whole-cell subsequent contraindica- such high possible permanent due identifiable shock-like hypotonic-hyporesponsive inconsolable whole-cell additional potential potential fourth fifth large-scale important specific larger operational serious other limited advisory other preventive acellular 40:881-2 adverse whole-cell 257:1351-6 acellular pertussis-component whole-cell pertussis-component 18-month-old 140:872-6 immune adverse conventional acellular acellular young acellular whole-cell 24-month-old 6:352-63 acellular clinical acellular acellular acellular acellular whole-cell pertussis-component 4- 6-year-old acellular pertussis-component diphtheria-tetanus- whole-cell pertussis-component 17- 24-month-old 69-kilodalton comparative acellular Placebo-controlled acellular acellular clinical invasive bacterial clinical acellular acellular acellular Japanese acellular acellular whole-cell pertussis-component System-United supplementary acellular recent second fourth fifth initial three-dose initial three-dose acceptable fourth supplementary late whole bacterial effective due safe adverse high antigenic acellular available due general likely acellular common adverse current whole-cell Several clinical relative protective primary acellular adequate single acellular fourth second fourth acellular filamentous combined ecologic Japanese other acellular placebo-controlled clinical similar old older acellular clinical equivalent initial three-dose fourth fifth similar higher Table available single-dose intramuscu- placebo-controlled clinical immunologic whole-cell fourth 15-20 fifth 4-6 * 24-fold 4-fold 15-20 4-6 whole-cell available formaldehyde-treated first second culture-confirmed culture-confirmed Non-blinded follow-up 42-month clinical other common systemic less fre- general local common systemic one-fifth general fourth fifth adverse fourth fifth 4-6 * 15-20 4-6 3-4 whole-cell available fourth fifth available local other common systemic specific particular other intermixed fourth routine simultaneous oral mea- complete general supplementary mild systemic such whole-cell / common self-limited symptomatic inconsolable > hypotonic-hyporesponsive epi- whole-cell similar Other more severe such prolonged enceph- temporal rare serious adverse such febrile common other preventive acellular supplementary acellular Noble Acellular whole-cell 257:1351-6 acellular Japanese Placebo-controlled acellular immuni- acellular acellular acellular whole-cell pertussis- / 388-392 397-400 oldest aggressive outbreak-control mea- major greater susceptible young self-limited subclinical long-lasting mumps-associated strong evi- high overall low due mumps-associated old serious rare central nervous 0.5-5.0 unilateral clinical testicular other experimental clinical permanent pancreatic direct spontaneous high live routine relative 3-year annual fivefold provisional school-aged first 5-year first reportable more dramatic eightfold susceptible young several recent high overall lower early previous lower sive comprehensive other mumps highest partial age-specific comprehensive recent attributable underimmunized routine 5–9-year-olds old comprehensive responsible mumps transient live subclinical noncommunicable few available efficacious susceptible measurable Vaccine-induced protective natural vaccine-induced unknown serologic epidemiologic live clinical different dry current susceptible favorable susceptible physician-diagnosed live first live age-specific likely recognizable arbitrary susceptible outbreak increased local live young necessary unreliable radial available single intramuscular effec- tive safe susceptible routine old live subsequent vaccine-associated adverse effective available low-grade uncommon mild brief mumps-containing greater normal Other such febrile usual nervous etiologic relation- congenital theoretical fetal prudent live pregnant pregnant theoretical final such mild upper severe live anaphylactic allergic anaphylactic Such usual anaphylactic neomycin delayed-type cell-mediated such adverse erythematous pruritic attenuated- least immune antime- general such live susceptible general human immunodefi- asymptomatic HIV-infected symptomatic least live topical nasal intraarticular corticos- extensive topical applica- Other pancreatic principal high young good other susceptible important young limited maximal susceptible oral necessary comprehensive severe medical-care susceptible affected local Such effective medical religious other least last affected other vaccine-preventable reportable suspected local other health-care permanent certain adverse Reportable adverse further adverse separate appropriate public federal local appropriate local Reportable private health-care susceptible single due serious low 31:617-20,625 1977-December 38:101-5 large further vaccine-preventable relative mumps- live mumps- Clinical serologic human 162:328-32 human live Clinical benefit-cost 136:362-4 mumps-virus human hypersen- sitive Safe mumps-measles-rubella egg-allergic human T-lymphotrophic lymphadenopathy-associated 35:595-8,603–6 human supplementary state- 37:181-3 permanent previous 33:301-10,315- new two-dose Current congenital common common manifestations- suboccipital erythematous pruritic low exanthematous other common subclinical many unrecognized joint nervous former likely important fetal therapeutic early first fetal auditory sensorineural ophthalmic cardiac pulmonary atrial ventricular septal neurologic microceph- mental purpuric severe recogniz- able first actual higher first least defect 20th fetal clinical maternal congenital average retarded hearing- sight-impaired other viral reexpo- natural clinical detectable many many unrecog- reliable specific reliable available school-age primary susceptible young characteristic 6- 9-year epidemic susceptible similar low constant endemic annual compatible late senior high susceptible military susceptible Many military military likely postpubertal higher private young lower young one-fourth postnatal lowest annual lowest -0.04 modest annual small available 20-70 annual indigenous postpubertal seronegative higher postpubertal live human higher greater least compatible congenital pigmentary subcutaneous subcutaneous monovalent rubella-mumps clinical susceptible single 11-13 clinical least 14-17 Available follow-up vaccine-induced long-term presumptive vaccine-induced lower vaccine-induced clinical natural similar natural small low detectable unknown rare clinical fetal disease-induced small 7-28 susceptible susceptible other pregnant such pregnant least Many new two-dose unreliable immune immune adoles- susceptible immune adequate permanent medical susceptible susceptible postpubertal fetal high-risk such military monovalent younger maternal seroconver- second second older junior high Initial high last recent preschool-age large urban entire smaller first available unvaccinated two-dose first reliable several available available live small rubella-susceptible pregnant live unknown compatible susceptible serologic subclinical serious attributable susceptible other less > aborted susceptible pregnant susceptible pregnant additional greater vaccine-associated negligible serious new due wild-virus vaccine-virus local susceptible pregnant pregnant reasonable pregnant pregnant conclusive live single unwarranted routine early useful pregnant previous anti-Rho human immune 6-8 other necessary C-8 dry susceptible susceptible susceptible susceptible postpubertal arthritis-like 26-28 peripheral neuritic such 1-3 joint susceptible neurologic carpal initial chronic other other such rare higher natural joint unclear viral peripheral substantial same defective partial immunoas- viral conclusive peripheral synovial susceptible conclusive pregnant pregnant severe susceptible such upper medical susceptible live Most minor anaphylactic anaphylactic neomycin delayed-type cell-mediated such adverse erythematous pruritic 48-96 live large corticos- wild serious live such such live symptomatic human least live low- moderate-dose systemic topical nasal long-term alternate-day low short-acting systemic intraarticular usual special such Asymptomatic symptomatic severe asymptomatic symptomatic serious unusual adverse variable 37-39 high-dose intravenous HIV-infected regular ineffective general simultaneous adverse similar individual different different important adverse oral different separate simultaneous eligible acceptable health-care simultaneous previous other health-care permanent adverse other adverse medical separate adverse public private reportable other serious unusual available 1-800-822-7967 widespread major immune susceptible immune 42-45 susceptible young routine postpubertal susceptible senior Such major high prompt further primary high Recent age-specific important such suscep- tible necessary successful mandatory military military young susceptible practical available potential prenatal susceptible effective expensive health-care necessary-one pregnant justifiable preferable high susceptible pregnant 3-month susceptible many susceptible preg- acceptable significant premarital aggressive susceptible pregnant such unlikely pregnant necessary recent 49-51 susceptible routine general medical family-planning routine pregnant other immune 52-55 medical prior rubella-immune day-care industrial high-risk large susceptible female least other important main susceptible active important important pregnant obstetric-gynecologic prenatal susceptible effective possible valid measles-outbreak medical religious other last rigorous such voluntary effective medical pregnant successful least substantial susceptible preferable less routine important long-term greatest new vaccine-induced other effective important local aggressive clinical other outbreak necessary specific many sensitive commercial newer commercial passive available detectable detectable specific sensitive small detectable follow-up 62-64 detectable sensitive rapid previous detectable clinical such low-level higher rare low such rare detectable sensitive available standard positive significant total recent other significant acute-phase possible first acute-phase significant used useful acute- convalescent-phase simulta- same significant first first rubella-specific likely 4-5 False-negative False-positive subclinical possible acute- convalescent- inconclusive rubella-specific necessary pregnant unknown difficult possible serologic Such prenatal such necessary diagnostic immune nasopharyngeal urine rubella-specific alternative rapid serologic older passive first nasopharyngeal urine negative endemic many international important susceptible maternal successive 11:781-4 ten-year 144:403-10 1970-1985 129:349-61 Stehr-Green congenital 134:350-3 5:237-41 live 1980:165:44-9 low 148:639-47 Clinical 2:284-6 protective live immune 21:25-31 school- 124:290-8 vaccine-induced immune natural 225:585-90 maternal 299:773-5 permanent current 254:253-6 joint 115:19-25 5:237-41 Japanese comparative 3:221-4 follow-up 127:684-8 immunological 40:22-8 Rubella-associated joint natural 154:368-9 rubella-associated immunologic virological 151:330-6 chronic young live HPV- human 261:2512-6 live human supplementary state- 37:181-3 measles-mumps-rubella polysaccharide-diphtheria toxoid 167-72 congenital 135:266-70 congenital 247:1129-33 congenital 1985- 38:173-8 245:1333-5 154:367-9 immuniza- maternal maternal immuni- Recommenda- 2:410-1,424 303:541-5 69:287-9 medical 248:861-4 34:615-8 32:394-5 1983-1984 34:228-31 32:349-52 285:253-5 sixteen-year Hawaiian 259:3133-6 live 280:1580-1 human live 165:260-3 young unimmunized 101:188-91 Available / Previous other medical international Personal School-based previous basic routine one-dose two-dose other higher health-care international severe middle ear permanent greater slow central nervous Widespread virtual spontaneous low-birth-weight first available more true entire several inactivated respec- live similar fewer effective single greater first collaborative voluntary medical greatest dramatic total different indigenous high careful aggressive local supplementary live first general physician medical difficult non-U.S. religious unvaccinated difficult unvaccinated recent major unvaccinated preschool-aged vaccinated school-aged substantial preschool-aged several inner- vaccine-eligible months-4 many 2-year-olds school-aged general high many higher older few older distant independent current large unvaccinated preschool-age substantial primary adequate secondary adequate effective lower transplacental secondary successful small Overall great long-term life-long further vaccine-induced current routine initial first second first immediate school-aged routine Special school- -40 likely substantial routine high overall intensive inner health-care contraindica- simultaneous other such other educational post-high first other other less second older preschool-aged last recent preschool-aged large inner-city urban entire physician-ciagnosed measlese available noncommunicable least susceptible vaccine-induced lower natural serologic epidemiologic vaccine-induced current thermostable 2-8 35.6-46.4 dry susceptible Available single M-M-R measles- preschool-aged low other medical medical direct Susceptible direct entire necessary such first second local physician-diagnosed “ perma- nent medical parental susceptible susceptible important substantial prior major potential substantial congenital additional such Other sensitive such enzyme many measles-specific detectable immune cost-effective large medical available first > second first 4-6 second administrative current other oral additional second necessary incomplete many recent 19-year-old second full second older middle junior high second high essential maximum two-dose second multiple complete school-aged live first least additional live first second local less Routine lower preschool-aged last recent preschool-aged large inner-city urban entire high-risk other post-high educational medical 1963-1975 immune available first acceptable effective first immune unknown unvaccinated unknown available available early other severe atypical natural such live inactivated live important natural international wide live Most mild local low-grade severe high extensive local serious natural same unknown unknown original first such second medical international immune physician-diagnosed adequate first second junior high acceptable older routine two-dose adequate first single acceptable higher second third acceptable adequate Similar second-dose first adequate preferable subsequent susceptible susceptible pregnant immunocompromised maximum least old Special other technical other post-high live prior other first second medical higher general laboratory medical direct other available medical medical medical least older occupational international young important other “ endemic epidemic 12-14 6-11 specific available first older unvaccinated optimal first low high-risk second local additional necessary More excellent 5-12 lasting several asymptomatic nervous healthy lower unknown severe neurologic adverse susceptible age-related small first personal idiopathic other neurologic Most simple febrile prior first-degree low large personal uncommon such vaccine-induced 5-12 difficult effective 5-7 alert available anticonvulsant phe- feasible personal small particular unlikely permanent medical small live previous natural pregnant next pregnant least theoretical fetal theoretical young pregnant theoretical current recent such mild upper-respiratory low-grade medical severe febrile adverse routine physical good severe appropriate live Most minor More immediate allergic anaphylactic anaphylactic such anaphylactic usual skin anaphylactic Most neomycin Live 1-2 live least whole other antibody-containing such serologic measles-specific international least subsequent serologic natural such other 4-6 large such symptomatic human live least live-virus low- moderate-dose systemic topical nasal long-term alternate-day low short-acting systemic intra-articular immunosuppressive usual special such Asymptomatic symptomatic severe asymptomatic symptomatic severe unusual adverse unpredictable 22-24 high-dose intravenous regular HIV-infected ineffective immediate passive possible symptomatic other previous usual effective such maximum maximum Intramuscular 100-400 last similar high-dose effective available general simultaneous adverse similar individual different different significant adverse different separate simultaneous eligible acceptable other health-care available concomitant simultaneous appropriate previous prompt susceptible adequate medical religious other least last School-based day-care elementary junior senior high other higher affected unaffected other first outbreak entire necessary difficult other special such routine high young natural first available first old adequate other medical medical older occupational Susceptible direct aggressive important special local suspected outbreak-control traditional significant acute- single proper important negative undetectable natural other permanent adverse other adverse medical adverse separate appropriate public adverse appropriate local private adverse 36:409-18,423-5 supplementary 38:11-4 maternal prospective 197:680-4 fetal 66:367-72 37:527-31 1985-1986 320:75-81 36:45-8 65:13-21 38:601-5 secondary 67:19-22 permanent previous clinical immunologic medical 255:1295-8 true adverse 1:939-42 hypersen- sitive 102:196-9 Safe mumps-measles-rubella egg-allergic 113:504-6 human 261:2512-6 live human supplementary state- 37:181-3 measles-mumps-rubella / 22-26 31-34 important inter- rupted primary primary annual paralytic more average annual less 1973-1980 small likely main- susceptible low higher first-grade indicat- primary higher lower wild universal important several live vac- individual primary Most single intestinal simultaneous wild special rare paralytic close 12-year Twenty-five healthy healthy many other subcutaneous great paralytic poli- Canadian available Additional available neces- sary comparable other present considerable epidemiologic wild in- wild paralytic Serious adverse current higher nary effective primary entire intestinal wild preferred American greater routine OPV-associated substantial available public higher gastrointestinal many high applicable available specific particular certain secondary mary 6-12 first least third 8-12 second high-risk additional first successful primary primary 4-to 8-week fourth 6-12 third primary primary early fourth third primary fourth fourth supplementary additional complete small single additional primary early least additional fourth primary fourth supplementary primary subsequent primary such supplementary available primary routine mary additional least poliovirus least equivalent higher complete primary Routine 6-12 6-12 6-8 4-8 Primary 4-8 8-12 6-12 third primary fourth fourth supplementary fourth primary fourth supplementary last complete primary routine primary additional least single primary old older necessary small poli- certain greater expo- sure general epidemic specific wild health-care primary feasible vaccine-associated higher 1-2 fourth 6-12 third least less available least available single increased full last increased supplementary primary additional small OPV-associated paralytic such prompt complete ex- OPV-associated poliovirus-vaccine usual responsible small acceptable strong ultimate full adverse pregnant prudent theoretical pregnant immediate such altered due such immune theoretical paralytic immune previous immuniza- wild-type per- paralytic less immuno- protective safe ad- household-type close maxi- other such other healthy Other available likely such small susceptible personal serious available sensitive immediate active other wild vaccine-derived epidemic unknown national 297:249-53 summary catch-up oral 45:444-8. inactivated 237:2228-30 young 246:1207-9 national 297:249-53 195:834-47 Vaccine-associated acute spinal oral 53:319-31 28:510-20 / 795-798 enhanced polio oral extensive potential current available 1961-1964 recent four-dose primary greater antigenic human several 4-6 clinical seropositive second seropositive 14-month second geometric mean 5- 10-fold second third available available unpublished lower third likely least good conventional recent vaccine-virus third enhanced- least great conventional less congenital such such other immunosuppressive other protective asymptomatic adverse such prudent wild normal poliovirus-vaccine overall vaccine-associated paralytic normal primary strong subsequent primary 0.5-ml first least third least nearer primary young third possible primary appropriate primary incomplete conventional final necessary primary primary final fourth additional unknown unvaccinated primary enhanced- 1- 2-month third less available available least available single least fewer conventional conventional fewer least Additional primary adverse low different human cell-derived local similar conventional serious serious older health-care adverse local appropriate federal such mild upper-respiratory severe anaphylactic adverse conventional pregnant available theoretical pregnant pregnant immediate 31:22-26,31-34 5:289-92 purified inactivated one- two-dose enhanced serologic oral injectable S552-5 oral antimicrobial American paralytic 257:1335-40 / RR-1 other older invasive bacterial effective invasive mental Ninety-five available available conjugate older different major invasive human independent primary independent poor 18-0 old variable smaller higher 18-71 old large ineffective 3-17 several post-licensure variable dependent independent present different older Table 2- 6-month-old difficult different non-Alaskan separate higher immunoge- Alaskan different 2- 6-month-old substantial immunologic immunologic geometric indicative long-term Similar different 7- 14-month-old available initial serum ug/mL unpublished separate initial 7-11 ug/mL available first small complex toxoid double-blind placebo-controlled geometric similar lower third subsequent similar Finnish other < 5-year-old recent unvaccinated full lower due placebo-controlled double-blind primary two-dose invasive personal early 5-7 PRP-D Post-2 -3 different definitive geometric unvaccinated 2-6 least old Table 12-14 single additional possible previous other short acceptable optimal unvaccinated 2-6 7-11 possible previous 12-14 single possible previous other short acceptable optimal 15-59 same entire different 2-6 primary available different primary invasive many adequate natural unvaccinated immune secondary extensive vac- 7-11 12-14 15-59 dose * 2-6 7-11 12-14 15-59 dose PRP-D 15-59 least previous primary unnecessary oral same simultaneous pneumococcal available older chronic good 1- 6-month-old simultaneous serious third second frequent Serious adverse healthy 6-12 serious adverse 2-14 second frequent meningococcal meningococcal 6:779-82 capsular double-blind 60:730-7 passive clinical infectious 1989:306-39 native bacteremic capsular 310:1561-6 323:1393-401 153:17-26 immunologic 1-to 6-month-old immunocompromised leukemic 161:926-31 143-4 immune first varicella- high-risk individuals-for immunocompromised postnatal normal pregnant certain contagious young serologic communicable secondary clinical 5-6 communicable longer immune viral large normal greatest normal small immunocompromised life-threatening serious life-threatening more benign passive maternal neonatal first fetal low hypotrophic ocular mental uncom- large available few susceptible likely older less older common latent clinical painful vesicular such generalized immunosuppressive common immunocompromised general generalized central nervous pulmonary hepatic pancreatic clinical susceptible normal immunocompromised lower-than-expected clinical higher-than-expected subclinical low low-titer high-titer available serologic clinical equivalent clinical ex- routine normal high sterile human continuous new regular greater likely susceptible greater general negligible substantial individual normal experienced immune second clinical rare subclinical rare normal old clinical susceptible other- other normal negative unknown such impractical available insensitive low clinical Other sensitive specific normal available immune ad- enzyme-linked available utilize sensitive free such higher immunocompromised sensitive available necessary current sensitive such immunocompromised clinical recent other fre- present sensitive nonspecific cellular further routine clinical tional sensitive useful young in- clinical detectable most such modi- fied prior actual susceptible prior clinical susceptible Table greatest such susceptible single available immunocom- susceptible clinical * experimental limited routine reliable unknown unnecessary susceptible normal unknown unnecessary susceptible immunocompromised unnecessary perform- unknown- immune general potential detectable trans- recent clinical further clinical clinical More such immune one-third VZIG-treated negative prior dis- one-fifth Significant same two- four-bed infectious direct infectious x-ray likely prolonged clinical normal utero high different much lower VZIG-treated important susceptible immunocompromised significant immune neoplastic immunosup- pressive necessary more pro- transplacentally-acquired increased significant postnatal Most indicated Continuous same two- four-bed adjacent large face- infectious such * other older pa- individual f. maternal transplacentally-acquired maternal immune postnatally-acquired unknown immune prudent negative uncertain Such con- less maternal transplacental maternal greater older normal-term likely greater normal negative unknown likely immune careful susceptible significant severe normal available clinical normal ninefold 25-fold greater normal normal normal individual negative uncertain previous older large sensitive available careful normal significant susceptible substantial normal such immunocompromised high-risk latter least normal same other pregnant negative uncertain prior first second congenital third neonatal susceptible preg- nant fetal immunosup- pressed significant clinical subclinical possible clinical normal with- fetal congenital neonatal pregnant susceptible intrauterine negative uncertain prior same other prior available sensitive necessary strict early possible possible positive immune Sero- logic useful negative uncertain susceptible Table significant direct direct general same susceptible receive clinical normal immunocompromised negative previous such one-third clinical infectious Many subclinical infectious vast immunocompromised VZIG-treated prolonged 10-28 maximum possible presumed effective late initial useful clinical such unknown reasonable last least immune globulin-approximately safe prior full normal immunocompromised appropriate likely suffi- normal Higher immunocompromised distribu- other Table adverse local frequent adverse such angioneurotic anaphylactic severe other intramuscular gamma 267:369-76 226:1521-4 other public medical contagious nephrotic immune regional 24-hour 24-hour 461-9800 American American 731-2130 American 678-2730 American 658-6400 American 446-7708 immune regional 24-hour 24-hour 256-2301 American 326-8888 American 255-5444 American 322-5661 American 482-3781 American American 494-2715 American 232-1176 American 484-7461 American immune regional 24-hour 24-hour 776-8754 American 247-9831 Canadian 623-0541 American other 292-1626 American 449-0773 American 1969:280:1191-4 neonatal varicella-zoster seventy-seven 58:692-6 further 290:243-5 newborn intensive 129:215-7 high-risk 129:616-8 high-risk Dose-response immune 68:14-7 1972-1977 140:257-60 low-birth-weight newborn intensive 103:113-4 147:737-43 passive intravenous practical 137:601-4 adverse adverse adverse adverse adverse adverse influenza-related capable other influenza adverse adverse adverse ii adverse Other .... specific available manufac- immune regional nervous anti-Rho pe- pediatric vac- medical immune immune previous specific vaccine-preventable specific adverse specific special life-style environmental individual detailed up-to-date individual current current specific pediatric widespread many vaccine-preventable successful specific substantial vaccine-preventable older natural safe vaccine-preventable unfounded adverse hospital professional private public voluntary common health-care unnecessary vaccine-preventable health-care older other vaccine-preventable pneumococcal certain occupational environ- life-style special increased vaccine-preventable foreign susceptible systematic necessary vaccine-preventable health-care several previous other health-care permanent certain adverse Table vaccine-preventable life-style such military advisable practitio- aware different military such responsible guardian major formal acceptable private medical available prospective federal similar many local available limited ample safe effective minor local severe systemic such oral Cause-and-effect adverse severe medical adverse detailed immunobiologics-including adverse necessary available most specific normal Vaccine-Preventable other essential young primary first least third 6-12 second primary unknown unvaccinated full three-dose immune new routine two-dose first second older middle junior high other post-high educational high health-care other endemic other young single live first physician-diagnosed new single first Acceptable live least first physician-diagnosed live mumps- and/or rubella-containing physician-diagnosed Physician adequate available unknown live-measles-virus least atypical likely susceptible more adequate 25-64 primary primary least third dose 6-12 second primary unknown unvaccinated full three-dose primary medical least live first physician-diagnosed immune health-care 1985-1989 health-care high small susceptible such susceptible such international Such live other likely susceptible other available susceptible more older least third dose 6-12 second primary unknown unvaccinated full three-dose primary older single pneumococcal highest fatal pneumococcal such asplenic chronic renal nephrotic certain vaccine-preventable Such various special occupational Vaccine-Preventable other essential infectious many health-care dental medical administrative medical possible vaccine-preventable consistent susceptible other major occupational health-care occupational percutaneous health-care public- blood-contaminated other increased human other infected occupational health-care occupational health-care serologic general susceptible health-care effective adverse additional available other outpatient-care high-risk essential public-safety health-care due considerable congenital therapeutic pregnant such medical other female pregnant such first susceptible disruptive costly such new Such immune live live first physician-diagnosed likely susceptible universal serologic immune health-care 1985-1989 medical least older occupational older old wild wild primary poliovirus vaccine-associated > vaccine- paralytic laboratory certain health-care clinical least antimicrobial aerosol occupational domestic wild human additional human frequent inadequate rapid fluorescent-focus western pneumonic domestic regular plague-infected likely other other typhoid certain vaccine-preventable active high homosexual possible homosexual high homosexual effective homosexual effective similar more anti-HBs milli-international high susceptible possible high unnecessary effective more anti-HBs active other female sexual previous vaccine-preventable additional Vaccine-Preventable other essential male environ- long-term correctional high homosexual long-term institutional serologic long-term such likely susceptible such high-risk human other infectious such possible current susceptible high effective new similar chronic medical high prenatal other susceptible vaccine-preventable such pneumococcal medical international likely seek good uncontrolled greater 1985-1989 unpublished other physician-diagnosed likely susceptible such European other vaccine-preventable such greater many such immune particular least elPV complete primary endemic vaccine-associated higher single primary last primary single supplementary single supplementary further southern previous such influenza available high previous current yellow meningococcal disease-specific yellow specific yellow many yellow appropriate local able vaccine-preventable specific many susceptible more high Susceptible sexual foreign appropriate appropriate certain other Table second third possible reasonable possible terato- least third dose 6-12 second last theoretical pregnant likely pregnant immediate yellow pregnant yellow international available noninfectious severe eligible Such positive effective other medical safe pregnant first reasonable theoretical undesirable pregnant pneumococcal pregnant high pneumococcal vaccinc-preventable sum- immunosuppressive annual pneumococcal single immunocompromised anatomic such substantial adverse minimal oral susceptible least live-virus exact individual asymptomatic Such symptomatic serious fatal Table 2-week topical nasal intra-articular immunosuppressive live-virus systemic effective normal available specific appropriate vaccine-preventable high environmen- serologic Susceptible long-term possible healthy lower individual proper additional anti-HBs Such anti-HBs anti-HBs renal chronic adverse annual current pneumococcal severe pneumococcal pneumococcal splenic fatal pneumococcal pneumococcal meningococcal meningococcal theoretical such elective pneumococcal meningo- coccal least Such serologic nonhemophilic multiple pneumococcal severe pneumococcal Such pneumococcal High-Risk adverse lower- respiratory-tract annual current congenital actual chronic pulmo- nary other severe chronic renal nephrotic such chronic pulmonary congestive Such pneumococcal other health-care permanent certain adverse pediatric pediatric permanent medical permanent health-care private public federal local Adverse additional other other serious unusual available 1-800-822-7967 civil traditional effective significant available 443-6593 available many specific adverse Table widespread 1985-1989 unvaccinated Limited 18-39 > protective 10-13 least effective large protective 10-13 other likely least third dose 6-12 second last primary widespread constant 48-64 unvaccinated pregnant temporary transplacental maternal 1982-1989 similar 18-39 > protective 10-13 medical receive 1987-1988 medical adequate effective prevent- active large protective 10-13 complete primary first least third dose 6-12 second primary aware different military last pediatric first active passive active primary toxoid complete primary toxoid long-lasting most complete primary vacci- 10-year clean minor 10-year additional other appropriate least full primary unknown uncertain passive recent sufficient careful primary many unknown uncertain previous previous active immuniza- large susceptible such susceptible passive human prophylactic separate separate Most adsorbed other systemic less common severe local 2-8 severe systemic such neurologic compli- teratogenic reasonable severe previous systemic allergic hypersen- appropriate immediate useful nonspecific skin-test common inconsequential cutaneous severe Arthus-type high other clean passive such mild severe routine Live-Virus measles-associated widespread all-time annual substantial large unvaccinated largest unvaccinated Twenty-five > hospitaliza- provisional measles-associated least epidemi- greatest spontaneous low noncommunicable single live durable susceptible medical least live first physician-diagnosed small susceptible such susceptible immune health-care 1985-1989 single live first long-lasting least most high immune sufficient nonimmune large young Other high other endemic high second desirable two-dose initial other post-high physician-diagnosed other second feasible other measles-containing second medical medical older occupational 1963-1967 live unknown 1963-1967 first least live other post-high medical least greater immune other uncertain live first physician-diagnosed likely protective acceptable immune effective medical 5-21 adverse 1-2 rare unknown lower natural live mild local low-grade Such severe atypical natural live previous natural such mild upper-respiratory severe least after-a whole other theoretical pregnant immune immuno- least HIV-infected susceptible live 48-72 recent 4-6 anaphylactic such anaphylactic live underimmunized young meningeal clinical rare sensorineural available single live protective long-lasting susceptible susceptible susceptible physician-diagnosed likely recognizable available live certain important recent vaccinated adverse uncommon mild central nervous greater general many live previous natural least least whole other theoretical fetal pregnant pregnant asymptomatic symptomatic anaphylactic severe anaphylactic fetal fetal therapeutic less older 1976-1979 least older current young susceptible employment-notably young high vigorous aggressive single live long-term susceptible susceptible available first positive particular susceptible routine internal routine premarital susceptible other available pregnant greater immune adverse susceptible postpubertal large-scale severe susceptible seropositive other 1-3 susceptible chronic high other other such rare higher natural transient such susceptible dose conclusive least least months-after adminis- other previous other human immune serologic 6-8 pregnant likely pregnant susceptible pregnant Ninety-four unknown compatible vaccine-associated small negligible final individual theoretical reasonable pregnant theoretical pregnant pregnant theoretical immuno- asymptomatic symptomatic human allergic allergic anaphylactic anaphylactic international civilian certain health- clinical civilian therapeutic other other smallpox vaccine 404-639-3356 404-639-1870 negative unknown likely immune severe normal immunocom- serious normal less varicella-zoster normal potential yellow fever-urban distinguishable identical yellow epidemic viral susceptible urban periodic recent other epidemic urban yellow enzootic viral nonhuman forest-savannah tropical 100-300 occupational underreported sporadic endemic forest yellow active unrecognized endemic yellow available live-virus single > local valid yellow many actual yellow yellow 10-year Other valid yellow individual current adverse mild low-grade other minor 5-10 Fewer regular hyper- uncommon occur fatal symptomatic immunosup- asymptomatic available adverse pregnant yellow small theoretical such international pregnant physician specific authoritative live yellow anaphylactic yellow questionable essential high medical 1-3 lower normal yellow minimum least 3-week small high general susceptible low Most immune primary > primary 6-8 third dose least second primary elPV 4-8 third dose 6-12 second primary primary greater general foreign OPV-associated higher older high old wild epidemic endemic primary available single full last primary single close wild wild primary susceptible immunocompromised adverse serious available possible anaphylactic anaphylactic healthy vaccine-associated paralytic small normal first subsequent normal first subsequent adverse pregnant pregnant immediate other live-virus other antibody-containing other harmful asymptomatic theoretical protective immune such immune small paralytic complete extreme OPV-associated poliovirus-vaccine responsible small such acceptable strong ultimate full appropriate Inactivated-Virus whole highest due active HBV-related HBV-related Plasma-derived inactivated alum-adsorbed 22-nm human available plasma-derived recombinant common three-dose first third dose second alternative fourth rapid clear greater standard least healthy possible available various susceptible effective subsequent such 1-6 health-care such more increased occupational social environmental illness-related homosexual heterosexual other sexual health-related frequent long-term correctional high endemic local short likely sexual high endemic eastern Such primary alternative four-dose better certain nonimmune high-risk protective second such normal single different acciden- tal percutaneous mucous-membrane sexual first sexual infected adverse common available plasma-derived first low true more Such available recombinant Early plasma-derived infectious such final available noninfectious chronic major lower dramatic able medical Such high recent high-risk medical major different attributable cardiopulmonary 1957-1986 excess major greatest new one-fourth more 2-3 elderly severe widespread human sufficient antigenic antigenic same same antigenic antigenic current such vaccinated young elderly young certain chronic lower young effective lower-respiratory-tract other upper- respiratory-tract other inactivated single important annual high lower-respiratory-tract elderly chronic pulmonary renal severe immune hospital-based population-based severe other common high high-risk subclinical mild Nosocomial such immune neonatal medical previous high-risk special greatest influenza-related high-risk other chronic medical pulmonary cardiovascular regular medical chronic renal months-18 long-term capable high-risk high-risk subclinical symptomatic high-risk elderly low other outpatient-care high-risk high-risk high-risk essential influenza elderly high-risk active other other medical safe pregnant first reasonable theoretical pregnant undesirable Little influenza HIV-infected recent high-risk prudent protective many low HIV-related immune other routine annual Other regular medical pneumococcal same different whereas pneumococcal polysaccha- antiviral adverse recent infrequent fewer other systemic persist 1-2 most systemic influenza immediate such various symp- likely residual current small anaphylactic influenza acute additional domestic recent wild important possible endemic likely single-dose lyophilized final single-dose available human available 1.0-ml 0.1-mL proper previous postex- three-dose three-dose adequate immune single 20-1U/kg 1-mL possible same same acceptable vaccine administra- high-risk certain more constant inadequate substantial infected other infectious open mucous carnivorous major domestic such local provoked adverse such such abdominal primary systemic mild immune- complex-like 2-21 allergic Fewer such primary neurologic reported-as different subacute central peripheral nervous other immunosuppressive active immunosuppressive unidentified enzootic least three-dose antimalarial possible 1.0-ml possible anaphylactic previous anaphylactic such public appropriate medical usual itinerary best 0.5-mL 0.2-mL single most complete available effective clinical low dubious longer cholera-infected individual many days- complete primary special high-risk endemic insanitary adverse 1-2 local specific available serious individual actual probable previous Most unvaccinated medical such unvaccinated yellow 1-3 lower normal yellow minimal least 3-week invasive invasive invasive pulmonary invasive Nontypeable common invasive such such available more immunogenic other hematologic immuno- good theoretical such functional such healthy protective lower healthy invasive close invasive unnecessary invasive asymptomatic other susceptible adverse 15-24 local surgical systemic pregnant theoretical pregnant substantial anatomic functional prudent endemic meningococcal single small localized meningococcal old Meningococcal meningococcal available single serogroup-specific unknown epidemic meningococcal terminal anatomic functional meningococcal low adverse meningococcal mild 1-2 meningococcal pregnant theoretical substantial prudent natural western Other many sporadic epidemic epizootic rural semirural second third second primary primary pneumonic unknown prophylactic certain vocational resistant antimicro- enzootic epidemic impossible endemic urban 0.1-0.2 1- 2-year good adverse vacci- general repeated urticarial asthmatic substantial severe local systemic serious pneumococcal available annual pneumococcal 15-19 old pneumococcal substantial pneumococcal highest medical older certain pneumococcal severe pneumococcal Other functional anatomic sickle multiple chronic renal nephrotic organ pneumococcal annual pneumococcal high pneumococcal cerebrospinal neurologic pneumococcal able responsible recent bacteremic pneumococcal Most healthy two-fold type-specific 2-3 single protective vaccine-induced unknown vaccine-induced healthy pneumococcal several pneumococcal vaccine-type bacteremic complete pneumococcal pneumococcal certain well-defined pneumococcal capsular 23-valent pneumococcal modest first highest rapid chronic renal nephrotic fatal pneumococcal Available broader pneu- mococcal pneumococcal chronic cardiovascular pulmonary old pneumococcal splenic anatomic chronic renal nephrotic such organ asymptomatic symptomatic special social pneumococcal certain Native effective other serious pneumococcal 5-year pneumococcal high-risk pneumo- coccal higher pneumococcal Office-based frequent medical pneumococcal pneumococcal different same pneumococcal pneumococcal independent prospective adverse pneumococcal polysac- such severe local such anaphylactic similar adverse first second local previous available highest pneumococcal pneumococcal pregnant high pneumococcal constant 1975-1989 1975-1989 other primary 0.5-ml phenol-inactivated live oral recommended acetone-killed available typhoid contami- smaller rural usual other selective natural least continued optimal live oral four-dose entire four-dose oral parenteral acetone-killed available adverse 1-2 local typhoid severe local systemic previous asymptomatic annual attributable greatest unrecognized untreated sputum-positive pulmonary early high many recent large-scale available percutaneous percutaneous other needle other high negative isoniazid preventive continuous active continuous high annual new adverse regional rare 1-10 immediate excessive infective prudent live-bacteria Other febrile young military oral available military other animal first 2-week other 6-month 0.5-mL 1-year available specific certain specific intravenous effective prophylactic several percutaneous mucous-membrane positive single possible different second identical percutaneous possible positive unclear percutaneous susceptible single last sexual sexual long-lasting Table alternative regular further necessary negative positive other documented adequate feasible 2-3 single more prolonged useful immune unnecessary sexual custodial such single possible effective susceptible maximum intravenous defective unusual available small 50-ml other clean minor previous unknown uncertain fewer previous prophylactic average same separate active available 404-639-3670 ocular possible therapeutic large 70-kg 24- 36-hour 2-3 new positive previous negative unknown likely immune tropical available greater normal susceptible significant close same two- four-bed direct such more severe normal normal individual normal lifelong previous older large normal substantial susceptible susceptible same other normal high-risk five-vial available normal higher necessary immunocompromised unknown last least adverse rare pregnant various other live-virus other least least live-virus other available reactive clinical high detectable low recommenda- 38:205-14,219-27 American clinical preventive large 144:296-8 medical settings-United 1985-1989 15-5S health-care 32:37-9 American elderly urban elderly 108:145-9 inner-city Tetanus-United 39:37-41 Adverse 247:40-2 hypersen- sitive 102:196-9 relative 142:499-507 immunological 40:22-8 Rubella-associated joint natural 45:110-4 last indigenous wild virus-associated viral neurologic adverse first 127:337-52 human final allergic human 33:185-7 human 248:3136-8 human 314:280-4 immunocompromised leukemic 161:926-31 112:143-4 immune American human pneumococcal 162:1012-7 pneumococcal pneumococcal 143:885-9 Simultaneous pneumococcal 247:2551-4 febrile pneumococcal pneumococcal 157:148-54 methodological statistical 249:2362-9 therapeutic human T-lymphotrophic III/lymphadenopathy-associated 35:231-3 human 26:210-3 immunoglobulin anti-HTLV-III adverse adverse anaphylactic hypotonic-hyporesponsive acute additional applicable anaphylactic additional adverse applicable nonimmunodeficient vaccine-associated acute contrain- additional applicable anaphylactic applicable additional vaccine/toxoid alphabetical pediatric compensable significant frequent focal neurologic intracaranial least neurologic temporary complete various permanent such high-pitched unusual inconsolable compatible conclusive slow * hypotonic-hyporesponsive such partial complete pale white unresponsiveness environmental other first mumps- other grand myoclonic tonic-clonic focal 18-24 25-64 specific adverse special 1-2 6-18 junior high 4-dose 3-dose same special envi- foreign other animal multiple sexual long-term special envi- foreign specific specific adverse special most individual more detailed enzootic epidemic situa- special anatomic other high-risk specific adverse special consid- most * human higher increased routine asymptomatic human * HIV-infected generic third dose 6-12 contra- neurologic immediate pre- vious severe local previous Such further live second least post-high medical Susceptible documen- live first physician-diagnosed anaphylactic susceptible live unknown revac- susceptible immune anaphylactic susceptible generic anaphylactic first young such military susceptible pregnant preg- nant vacci- theoretical vaccine-associated malfor- small negligible likely susceptible health-care clinical recombinant specific infor- available adverse prudent theoretical pregnant yellow valid pregnant international primary third elPV 6-12 immediate wild epidemic endemic health-care safe con- docu- adverse pregnant prudent theoretical pregnant immediate polio- such increased occupational environmental social INACTIVATED-VIRUS inactivated-virus third second necessary primary fourth third available noninfectious negligible eligible therapeutic adverse HBV-infected effective generic current whole- split-virus high-risk other chronic-care medical-care healthy anaphylactic fetal underlying high-risk preg- nant reasonable second third possible third second inadequate certain constant additional substantial immunosuppressive active anaphylactic previous treat- expo- contami- previous previous current recommended generic possible 0.5-mL 0.2-mL specific preg- actual severe local systemic previous complete primary care- ful highest theo- retical anatomic func- tional available invasive generic unknown epidemic meningococcal substantial second third mL second 1- 2- impossible organ- enzootic wild substantial unavoid- able per- severe local systemic previous highest increased pneumococcal older healthy pregnant high pneumococcal highest oral local systemic previous Acetone-killed careful more mL oral entire four-dose unavoidable untreated active excessive new other successful tuberculosis-control identifi- preventive generic immune intravenous 50-100 contin- ued 3-4 effective 2-3 anticipated appropriate careful sexual attend- maximum susceptible live generic possible different second sexual percutaneous positive sexual immune nonclean unknown previous previous more old pre- postexpo- preferable first generic 24-36 2-3 new ocular likely susceptible infectious further adverse special individual other immune available available trivalent available eastern western available second third possible reasonable yellow total prophylaxis other specific adverse special old toxoid old fourth last last frequent percutaneous negative unknown positive anti-HBs positive anti-HBs unknown anti-HBs inadequate adequate positive sexual last sexual appropriate age-specific first same different endemic 219-27 Calmette-Guerin 37:663-4 37:617-24 :1-28 viral lymphadenopathy-associated RR-2 1-26 35:595-8 603-6 37:181-6 supplementary 34:255-9 38:388-92 397-400 31:301-4 31:22-6,31-4 36:795-8 33:84-90,95-100 available upcoming Physician Elderly American Infectious American due Other immune polysaccharide- oral Acetone-killed oral/Ty21A Swiss immune best accurate complete current available various — Lederle-Praxis Swiss female neonate attenuated- low susceptible post- first Questionable attenuated- congenital syndrome theoretical susceptible post- attenuated- expo- sure high preferable possible female neonate tetanus- tetanus- primary diph- severe occur 1- 2-month third dose 6-12 second single first fetal neonatal attenuated- 4-8 third dose 6-12 second 6- 8-week third least susceptible pregnant endemic other high- third prema- HBsAg-positive neonate peri- natal trans- possible Possible new antigenic serious public authori- con- current public pregnant same maternal severe maternal international 4-8 low neonate third third available unusual maternal available high highest fatal such recom- primary close con- expo- endemic single oral third prematu- possible possible incuba- possible third Possible prema- peri- natal trans- HBsAg-positive possible chronic fulminant low maternal killed-virus pregnant agent vial indicat- severe healthy pregnant neonatal de- clinical acceptable other acceptable sirnilar 24-hour American 623-0541 northern southern 326-8888 American southern 24-hour northern southern 494-2715 American 232-1176 American 24-hour northern southern 247-9831 886-6866 American 24-hour 425-1647 376-1661 781-1800 American 24-hour 791-6250 American 776-8754 American northern 359-5100 American Other other 449-0773 American previous viral 34:313-24,329-35 1987,36:353-66 pregnant perinatal 37:341-46,51 other viral 34:313-24,329-35 viral several similar infectious separate early specific serologic third non-A non-B distinct parenter- non-A non-B non-A non-B sporadic least different non-A non-B fecal-oral different distinct acute non-A non-B unspecified young many incomplete actual several important medical sterile human large free immune anti-HAV anti-HBs high other available late reactive clinical high detectable low Serious intramuscular intravenous other prophy- pregnant 27-nm abrupt abdominal asymptomatic ill case-fatality person-to-person fecal contami- oral poor personal poor sexual recent intravenous likely due person-to-person Common-source 15-50 average highest early prodromal 2-week chronic uncommon early detectable available total lower common older young attributable past protective clinical 11-13 prophylactic greatest current major international 14-16 general western greater highest rural poor recent many travel-related standard unpub- other unknown uncooked uncooked susceptible important rural poor uncertain close local young poor sanitary single total anti-HAV useful unnecessary most developed clinical serologic anti-HAV costly single possible last Specific personal sexual important 18-20 more elementary secondary important epidemiologic school- classroom-centered close such close epidemiologic entire direct infective incontinent neonatal intensive usual fellow casual effective waterborne common 2-week effective possible uncommon other infected hygienic such institutional stronger infectious single recent anti-HAV detectable 4-6 large several high commercial available Anti-HBs recent detectable anti-HBc 4-6 early least candidate non-B large fecal-oral waterborne low-titer immune 42-nm double-shelled deoxyribo- Several well-defined excess 22-nm spherical tubular 30-60 variable responsible long-term anti-HBc anti-HBc early reliable recent third chronic viral high most lower long 45-160 average insidious abdominal such variable infected central HBsAg-positive least least HBsAg-positive anti-HBc negative single positive infectious HBsAg-positive acute highest serous lower present other such percutaneous infective sexual continuous close personal such unnoticed infective rare routine current uncommon invasive oral gynecologic HBsAg-positive health-care potential aseptic fecal-oral major chronic primary hepatocellular different low most other endemic endemic other local recommen- young require infectious chronic active primary 12-300 higher other B-related uncommon general certain high certain endemic Alaskan homosexual nous early high heterosexual significant high parenteral custodial sexual certain plasma-derived anti-hemophilic occupational medical higher attributable several intravenous heterosexual various serologic high 70-85 5-15 40-70 disabled 10-20 35-80 illicit parenteral 60-80 active homosexual 35-80 3-6 30-60 3-10 20-80 workers- frequent 1-2 15-30 1-8 10-80 disabled 10-25 multiple 5-20 3-10 multiple homosexual present high Most occupational major other high-risk high-risk comprehensive pregnant previous selective HBsAg-positive pregnant alternative possible available active temporary certain high anti-HBs final alum-adsorbed 22-nm human biophysical urea human other immunocompromised common biochemical more Yeast-derived more final 10-40 intramuscular adequate healthy lower normal protective high necessary other such immunosuppressive clinical susceptible millilnternational positive enzyme 1-6 complete detectable viremic clinical 36-38 lower normal last adequate intramuscular second third first older full complete available alternative rapid clear greater standard three-dose deltoid anterolateral other immunosuppressed higher special available such higher unknown satisfactory optimal third first second third 3-5 late third necessary different comparable single available similar likely such comparable low plasma-derived intradermal several largest lower low intradermal low appropriate ug ug Other 11-19 other Usual other immunocompromised Alternative 1.0-ml different eligible other available noninfectious severe eligible shipment frozen adverse common available plasma-derived first low more true Such available recombinant Early unfounded infectious such final therapeutic adverse previous necessary Such anti-HBs transplacental active potential prior immune highest cost-effective high marginal low such cost- effective routine necessary Anti-HBc particular such health-care unnecessary higher usual positive positive appropriate serologic protective healthy subsequent such such occupational needle-stick necessary definitive additional additional primary additional vaccine-induced low undetectable normal immune routine necessary necessary possible longer additional available vaccine-induced complete annual substantial likely susceptible occupational major infectious occupational health-care occupational percutaneous permucosal health-care blood-contaminated such other health-care highest professional possible other first disabled Susceptible institutional other infective Susceptible smaller residential residential appropriate environmental appropriate nonresidential day-care devel- day-care special medical serous susceptible anti-HBs lower healthy higher renal active homosexual active homosexual homosexual possible homosexual bisexual anti-HBs injectable injectable susceptible possible certain specific multiple sexual high greatest diagnostic certain other sexual susceptible high unaccompanied high intermediate HBsAg-positive Other casual such minimal child-care special such medical severe high certain Alaskan such universal extensive available endemic eastern susceptible susceptible high interfamilial endemic long-term favorable injectable male homosexual percuta- neous high-risk active heterosexual active heterosexual multiple sexual sexual other sexual previous more high endemic close local short-term likely sexual high endemic least full partial alternative four-dose better first second third first perinatal infant HBsAg-positive accidental percutaneous HBsAg-positive sexual HBsAg-positive primary relative different perinatal HBsAg-positive HBeAg-positive effective 35,49-51 multiple percutaneous effective sexual single effective last sexual uncertain available future short- long-term costly two-dose perinatal efficient long-term HBsAg-positive HBeAg-positive chronic primary hepatocellular HBsAg-positive HBeAg-negative lower such acute fatal HBsAg-positive chronic pregnant HBsAg-positive effective pregnant early same other routine special such intravenous additional other necessary maternal HBsAg-positive chronic available possible HBsAg-positive negative initial positive same HBsAg-positive stable appropriate first different available first possible Subsequent specific 12-15 detectable anti-HBs useful maternal routine sexual susceptible pediatric HBsAg-positive follow-up prenatal hospital-based obstetrical pediatric proper follow-up HBsAg-positive other susceptible sexual certain Alaskan endemic practical such extensive available percutaneous needle ocular mucous- several available Such last sexual appropriate first same different such anti-HBs percutaneous greatest passive possible unclear single possible possible first Table separate specific exposed adequate last current vaccine-induced prudent anti-HBs adequate necessary anti-HBs primary single possible possible second least anti-HBs unknown adequate millilnternational positive percutaneous HBsAg-positive HBsAg-negative unknown anti-HBs adequate inadequate HBsAg-positive unknown anti-HBs anti-HBs inadequate adequate positive adequate additional necessary inadequate different necessary unknown available first adequate necessary HBsAg-positive high anti-HBs unknown adequate necessary inadequate effective such sexual effective other unlikely sexual last susceptible sexual sexual single last sexual sexual long-lasting alternative regular sexual necessary sexual sexual HBsAg-positive second primary higher primary other identifiable such Such sexual defective active 35- 37-nm viral single-stranded internal clinical chronic chronic active early total IgM-specific anti-HDV total anti-HDV available Other available similar high parenteral susceptible sexual percutaneous positive such high parenteral male homosexual available NON-A NON-B non-A non-B viral similar responsible non-A non-B substantial chronic potential non-A non-B transfusion-associated 61-64 high parenteral frequent personal non-A non-B 63-65 person-to-person sexual unclear non-A non-B same due different bloodborne non-A non-B chronic present perinatal non-A non-B small acute non-B 4-8 equivocal several non-A non-B 70-72 percutaneous non-A non-B reasonable possible other specific distinct non-A non-B fecal-oral large waterborne non-A non-B other middle-aged affected high pregnant experimental non-A non-B endemic unknown causative present non-A non-B infected other enteric best non-A non-B non-A non-B 1:17-31 blood-borne non-A non-B 244:359-62 major etiologic human non-A non-B 244:362-4 Waterborne non-A non-B 3:729-37 therapeutic human III/lymphadenopathy-associated 35:231-3 human 26:210-3 immunoglobulin anti-HTLV-III neonatal intensive 252:2711-5 viral medium-size 174:469-77 infectious preliminary 127:144-5 infectious 219:1191-3 immune 209:1053-8 156:84-91 international day-care 242:1514-8 day-care community- wide 302:1222-7 249:48-53 viral Food-borne 148:1133-5 resultant surgical 255:934-7 dental 110:634-6 pregnant 37:341-6,351 routine 256:869-72 clinical recombinant Clinical yeast-derived controlled clinical high-risk 303:833-41 311:496-501 human suboptimal 109:101-5 Yeast-recombinant ofperinatal 257:2612-6 homosexual 261:2362-6 necessary 109:457-8 Clinical low-dose 254:3203-6 neurologic adverse first 127:337-52 chronic Passive-active 1:575-7 254:3190-5 chronic 1985:5-6 chronic renal 157:332-7 endemic medical 6:431-7 Asian 321:1301-5 2:1099-102 newborn chronic hepatitis-B hepatitis-B placebo-controlled 1:921-6 passive-active 253:1740-5 perinatal final perinatal preliminary double-blind placebo-controlled comparative needlestick accidental medical final 138:625-38 immune prophylactic 293:1055-9 hepatocellular 1984:209-24 acute icteric antigen-positive anti-hepatitis early HBsAg-positive pregnant non-A non-B 1985:71-9 Clinical serological transfusion-associated 2:838-41 non-B clinical non-A non-B urban 145:886-93 heterosexual non-A non-B 262:1201-5 Non-A non-B 139:634-40 Non-A non-B clinical 6:67-81 non-A non-B transmissible six-year 303:140-3 alanine non-A non-B Transfusion-Transmitted maternal-infant / previous 34:313-24,329-35 36:353-66 pregnant peri- natal 37:341-46,51 other viral 22-26 comprehensive major acute new million-1.25 chronic infectious many long-term such chronic hepatocellular chronic effective recommended selective feasible many identifiable early important high infected pregnant positive high Alaskan comprehensive routine perinatal HBV-infected chronic perinatal HBV-infected high HBsAg-positive pregnant high HBV-infected pregnant prenatal HBsAg-positive least chronic chronic high endemic acute American endemic HBsAg-positive prenatal HBsAg-negative immigrant high other most Several specific sexual homosexual multiple heterosexual parenteral occupational chronic certain one-third identifiable various racial ethnic greater previous major unpublished aware high unpublished susceptible sexual substantial little overall widespread occupational sexual important homosexual parenteral heterosexual likely high-risk responsible defective active active fulminant similar high susceptible comprehensive evident high current medical chronic new susceptible new susceptible Routine well-child comprehensive pregnant perinatal routine HBsAg-negative certain adoles- high routine health-care additional incremental additional health-care immuni- widespread at-risk such susceptible infant high previous infant apparent pregnant direct medical unpublished same other expensive higher higher long universal infant high-risk available long-term temporary 3-6 certain high anti-HBs anti-HBs human final available recombinant common biochemical biophysical intramuscular protective anti-HBs milli-international healthy 31-33 deltoid anterolateral same other separate anterolateral preferable such standard low lower lower final anti-HBs 35-38 plasma-derived comparable Plasma-derived adequate low-dose inadequate anti-HBs full apparent adverse noninfectious pregnant severe chronic intramuscular second third first rapid clear greater standard three-dose age-specific general Table protective anti-HBs three-dose first second little final optimal last 4-12 higher final high last necessary highest final same other other first second possible second third least third immune subsequent different comparable full single protective high necessary other immuno- immunosuppressive positive few available higher most low low higher ug ug HBsAg-negative HBsAg-positive perinatal 11-19 other immunocompromised three-dose four-dose * Special 1.0-ml four-dose high homosexual already-infected immune careful patient follow-up routine necessary anti-HBc anti-HBs Anti-HBc anti-HBs particular such health-care preferable unnecessary high Such necessary subsequent clinical HBsAg-positive occupational sharp appropriate necessary HBsAg-positive primary adequate additional additional more additional immunoprophylactic various perinatal HBsAg-positive appropriate effective 11-12 Sexual-acute contact- contact- acute contact-acute < primary three-dose four-dose effective pose clinical positive few likely due high maternal perinatal long-term medical few anti-HBs other previous effective clinical susceptible protective clinical vaccine-induced long-term follow-up plasma-derived longest clinical comparable short-term similar primary predictive logarithmic young homosexual three-dose lower comparable same healthy immunologic intact least chronic anti-HBs low detectable clinical infrequent chronic general high chronic least immune normal necessary possible additional available vaccine-induced less complete annual safe least many Vaccine-associated greater side 5,31-33,50 placebo-controlled Serious adverse possible first plasma-derived recombinant 1986-1990 Available adverse large-scale plasma-derived severe systematic adverse small adverse chronic current HBV-related routine important current adverse 1-800-822-7967 pregnant early same other routine negative high apparent other necessary maternal HBsAg-positive positive intramuscular different prenatal HBsAg-positive positive additional possible important second high last Table four-dose second third fourth 12-18 negative feasible first second 1- third well-child Table HBsAg-positive prenatal susceptible susceptible HBsAg-Negative first newborn positive positive possible birth Second 1-2 appropriate different four-dose third fourth 12-18 HBsAg-positive positive negative appropriate negative -negative 1-2 6-18 1-2 6-18 diphtheria-tetanus- oral same highest last preferable Table 2-month other good Table appropriate difficult other optimal Special high high high more partier/6 Widespread universal common school-based special 0- 1- 6-month advisable complete high Table High-risk occupational occupational health-care public-safety occupational ous permucosal blood-contaminated health-care blood-contaminated preex- other first disabled Susceptible smaller residential residential appropriate environmental appropriate nonresidential comparable other lower special medical exudative open serous susceptible renal likely anti-HBs lower healthy frequent certain specific multiple sexual positive susceptible susceptible endemic unaccompanied endemic positive other more high local likely medical sexual high intermediate endemic least full partial four-dose first susceptible high anti-HBs active homosexual active homosexual bisexual high anti-HBs active heterosexual other sexual previous long-term correctional high-risk clinical operational most first pregnant protective protective current optimum new available routine additional certain viral alternative 263:1218-22 11:84-92 passive-active 253:1740-5 Yeast-recombinant perinatal 257:2612-6 comprehensive 2:1134-6 anti-HBe vertical 3:237-41 preliminary double-blind placebo-controlled comparative 1984:209-24 Postnatal antigen-carrier 147:185-90 large municipal obstetrical 107:335-7 pregnant American 1991:238-55 prenatal American clinical subsequent 151:599-603 viral 66:443-55 118:543-9 110:227-36 Asian 321:1301-5 infection-United 1976-1980 38:818- positive 1991:728-9 human 52:41818-24 3:729-37 human 749-66 alfa-2b chronic 323:295-301 prenatal 259:365-9 therapeutic human T-lymphotrophic III/lymphadenopathy-associated 35:231-3 human 26:210-3 clinical recombinant yeast-derived 145-20s controlled clinical high-risk 303:833-41 anatomic immune 7:425-30 Clinical low-dose 254:3203-6 large intramuscular intradermal recombinant 17:126-9 12:1035-43 recombinant antigen-positive 3278-81 different 160:766-9 7:106-10 Simultaneous diphtheria-tetanus-pertussis-polio 151:784-7 311:496-501 recombinant 3:190-5 human suboptimal 101-5 Long-term homosexual maternal-infant 6:369-73 multi-center homosexual 261:2362-6 Long-term HBeAg-positive plasma-derived perinatal 1991:759-61 neurologic adverse first 127:337-52 1991:716-9 40:5-6 perinatal final 3:135-41 human chronic renal serologic 3:201-4 endemic medical 6:431-7 perinatal infant HBsAg-positive percutaneous HBsAg-positive sexual HBsAg-positive primary relative different perinatal HBsAg-positive HBeAg-positive effective multiple perrcutaneous effective sexual single effective last sexual uncertain available future short- long-term costly two-dose percutaneous needlestick ocular mucous- several available Such such percutaneous greatest passive possible unclear positive single possible possible first separate subsequent specific exposed adequate last current vaccine-induced prudent anti-HBs adequate necessary anti-HBs primary single possible possible second least anti-HBs unknown adequate additional necessary inadequate different necessary unknown available first adequate percu- taneous positive negative anti-HBs adequate inadequate positive unknown anti-HBS anti-HBs inadequate adequate adequate > milli-international adequate necessary HBsAg-positive high anti-HBs unknown adequate necessary inadequate effective such sexual effective other unlikely last susceptible single last sexual sexual long-lasting regular further necessary negative positive primary higher less primary other identifiable such Such sexual Yeast-recombinant perinatal 257:2612-6 2:1099-102 passive-active 253:1740-5 perinatal final 3:135-41 preliminary double-blind placebo-controlled comparative needlestick final medical final 138:625-38 immune prophylactic 293:1055-9 / Other Other Other antiviral available primary other optimal widespread human little other antigenic related same major respiratory new antigenic Typical nonproductive other common severe several severe primary secondary high walk-in lower-respiratory-tract such high-risk influenza-related likely general major high-risk 2- 5-fold healthy younger influenza-related relative less high-risk cardiopulmonary other chronic excess different more excess elderly severe younger influenza-related various such neonatal intensive better such cystic better organ-transplant available killed-virus influenza-specific antiviral high-risk effective cost-effective likely high-risk routine special unnecessary epidemic Other strong influenza high-risk antiviral available amantadine effective maximum potential potential greatest severe high-risk ill short-term late high-risk seasonal seasonal immunocompromised unvaccinated health-care high-risk egg-grown noninfectious likely such systemic available febrile young high protective similar outbreak certain chronic lower healthy young susceptible upper-respiratory-tract such influenza effective lower-respiratory-tract other medical high-risk influenza 1992-1993 45/90-like different current more previous annual current necessary 1991-1992 1992-1993 least satisfactory unvaccinated similar current little second same adequate recent other intramuscular older young anterolateral high-risk close Influenza-Related other chronic medical pulmonary cardiovascular 6-35 3-8 ug lower febrile split-virus purified-surface-antigen split- whole-virus similar young anterolateral least regular medical chronic renal long-term High-Risk high-risk high-risk elderly low high-risk other outpatient-care high-risk high-risk high-risk influenza essential essential other institutional such routine pregnant pregnant other medical safe pregnant first reasonable theoretical undesirable pregnant first human recent serious prudent protective many low HIV-related immune elderly high-risk medical interna- tional foreign southern greatest short clinical potential southern previous influenza high-risk available previous current anaphylactic other such anaphylactic higher appropriate preferable minor mild upper allergic American noninfectious unrelated frequent less systemic other systemic most affect young such allergic likely residual current small severe appropriate eggs- occupational other allergic similar medical subsequent other influenza adverse clinical attributable influenza potential most intradermal indicate local delayed-type pneumococcal same different whereas pneumococcal highest fatal pneumococcal high influenza-related same pneumococcal oral different available high-risk health-care high optimal high-risk mid-October early high contiguous important such few current available regional earlier least satisfactory second possible optimum medical regular appropriate high-risk influenza effective high-risk general successful health-care potential administrative financial medical medical possible minimal lowest possible walk-in familiar influenza high-risk available Other Residential individual younger high-risk influenza High-Risk hemodi- such earlier influenza High-Risk high-risk necessary unvaccinated specific influenza appropriate appropriate educational particular high-risk intensive-care newborn intensive-care medical/surgical other available follow-up antiviral specific amantadine specific antiviral healthy young epidemic effective healthy young symptomatic other systemic rapid daily antiviral subclinical small Such severe important high-risk early possible rapid short amanta- previous unvaccinated high-risk effective antiviral first second high-risk high-risk institutional unvaccinated high-risk unvaccinated entire variant poor many available possible other Such influenza appropriate high-risk anaphylactic other Other individual healthy high-risk specific therapeutic high-risk compatible effective first healthy young minor gastrointestinal approxi- diminish serious frequent CNS-related elderly other behavioral mg/day such compro- prophylactic other medical impaired renal elderly neuropsychiatric resistant unknown amantadine-resistant transmissible amantadine-sensitive appropriate such possible asymptomatic possible advisable amantadine influenza-like 3-5 antiviral available several local clinical influenza epidemic influenza 1970-79 Serious influenza 1986:63-73 acute pregnant 142:360-2 epidemic influenza non-institutionalized elderly 1986:169-82 5:737-47 prospective elderly school-aged elderly clinical influenza systemic thimerosal allergic influenza ascorbic adverse asthmatic Other pneumococcal infectious American pneumococcal HIV-infected homosexual two-dose human human human cruise-ship hospital nosocomial hospital-based medical national institution-wide infectious healthy elderly influenza institutional apparent rimantadine-resistant normal impaired renal possible young high-risk Protective low-dose wild-type anti-influenza last pneumococcal new human other pneumococcal important young elderly certain recent pneumococcal best serious pneumococcal community-based pneumococcal annual old old overall pneumococcal Native American general pneumococcal estimated pneumococcal pneumococcal highest medical older bacteremic appropriate antimicrobial sensitive young old certain pneumococcal severe pneumococcal pulmonary Other greater rapid serum functional anatomic sickle multiple chronic renal nephrotic organ recent population-based old pneumo- coccal least chronic pneumococcal annual pneumococcal high consistent pneumococcal cerebrospinal neurologic current pneumococcal capsular Danish 14-valent capsular bacteremic pneumococcal human several additional Most healthy greater type-specific alcoholic less old capsular poor important pediatric pneumococcal old healthy pneumococcal pneumococcal least rapid undergone nephrotic pneumococcal asymptomatic HIV-infected lymphadenopathy 23-valent pneumococcal pneumococcal young healthy high systemic pneumococcal other unpublished prospective overall protective pneumo- coccal vaccine- vaccine-related protective cardiac renal old other high-risk chronic old smaller pneumococcal inadequate pneumococcal vaccine-type bacteremic chronic pulmonary unvaccinated sterile pneumococcal clinical unpublished double-blind placebo-controlled high-risk pneumococcal uncertain pneumococcal French clinical pneumo- coccal effective pneumococcal certain well-defined pneumococcal cardiovascular pulmonary old pneumococcal splenic anatomic chronic renal nephrotic such organ asymptomatic symptomatic old pneumo- coccal anatomic functional nephrotic cerebrospinal immuno- old asymptomatic symptomatic available 23-valent upper special social pneumococcal certain Native American pneumococcal such severe local such pneumococcal pregnant high pneumococcal elective pneumococcal least possible immunosup- pressive least local severe initial large elderly least primary similar such primary 14-valent pneumococcal 23-valent modest 23-valent 14-valent highest fatal pneumococcal asplenic highest 23-valent rapid pneumococcal nephrotic nephrotic old pneumococcal American pneumococcal cost- effective high-risk annual pneumococcal serious pneumococcal pneumococcal serious pneumococcal least pneumococcal few pneumococcal effective pneumococcal other Many pneumococcal different pneumococcal immunogenic pneumococcal old protein-polysaccharide British British prognostic 62:195-220 pneumococcal local 21-62 local 28-35 primary 2-5 local 23-40 24-48 primary 8-9 10-27 serious local 4-23 severe local axillary Cumulative net due relative American immune pneumococcal immune second-generation pneumococcal cross-reactive pneumococcal younger 14-valent pneumococcal pre-school pneumococcal healthy splenectomized pneumococcal Long-term pneumococcal sickle 105:261-3 vaccine-induced antipneumococcal nephrotic anti-pneumococcal AIDS-related persistent pneumococcal HIV-infected homosexual Austrian pneumococcal pneumococcal pneumococcal- Austrian pneumococcal protective pneumococcal high serious pneumococcal protective pneumococcal clinical pneumococcal elderly pneumococcal high-risk pneumococcal high-risk pneumococcal pneumococcal normal pneumococcal pneumococcal pneumococcal pneumococcal 37:361-4,369–73 previous 27:327-9 available civilian endemic epidemic meningo- second common bacterial approxi- meningococcal such sensitive major meningococcal endemic meningococcal early highest 6-12 available major small endemic common epidemic certain meningococcal common deficien- final common many multiple epi- meningococ- cal other higher meningococcal other new military high uncommon available vac- ug bacterial clinical young comparable good 18-24 clinical similar clinical American military safe immunogenic 6-9 clinical as- clinical serogroup-specific independent first single 5,10-13 rapid young vaccine-induced clinical least recent marked young effica- greater less older meningococcal low major available meningococcal young due other reasonable endemic uncommon older young higher Routine particular high-risk terminal anatomic functional acceptable meningo- coccal clinical such hy- perendemic epidemic local meningococcal sub-Saharan other updated single same other Good 10-14 infrequent princi- 1-2 young theoretical pregnant substantial pregnant epidemic adverse good few subsequent such high older unknown meningococcal capsular meningococcal outer- available preventive sporadic oral such mouth-to-mouth general causative sensitive rifam- child- effective serious adverse teratogenic urine systemic antimicrobial meningococcal important helpful unne- preventive meningococcal 1975-1980 148:754-8 neisserial other immune 63:243-73 61:135-55 meningococcal first routine 140:690-7 meningo- coccal 34:725-32 meningococcal clinical serological 10:335-9 new tetravalent meningococcal te- meningococcal O-acetyl-negative O-acetyl-positive 42:599-604 polysaccharide-vaccine-induced child- meningococcal meningococcal African 142:861-8 5:71-91 meningococcal 76:115-21 meningococcal 65:1141-4 upper intravenous antibiotic systemic meningococcal 151:370-1 255-259 / 181-186 severe fatal HIV-infected previous HIV-infected asymptomatic severe symptomatic serious unusual symptomatic HIV-infected consistent symptomatic HIV-infected asymptomatic such younger such older 12-14 high-dose intravenous regular HIV-infected susceptible asymptomatic measles-susceptible pregnant maximum symptomatic such maximum maximum Intramuscular necessary 100-400 regular last high-dose effective symptomatic HIV-infected desirable unrecognized possible unvaccinated physician previous other current HIV-infected Table HIV-infected routine 2:669-72 37:183-186 human III/lymphadenopathy-associated live HIV-infected retrospective human 62:5-9 36:409-18,423-5. routine HIV-infected previous 595-598 603-606 Lymphadenopathy-Associated available health-care develop- human III/lymphadenopathy-associated syn- inci- vaccine-preventable individual particular vaccine-preventable other different vaccine-preventable available specific vaccine-preventable HTLV-11I/LAV 1981-September forty-five severe AIDS-related asymptomatic infected asymptomatic uncertain symptomatic HTLV-III/LAV-infected first Sixty-five pediatric fatal lower severe opportunistic ultimate Most major intravenous sexual in- bisexual Haitian central higher small pediatric incomplete human lymphadenopathy-associated AIDS-associated human human immunodefi- appropriate available pediatric perinatal infected prospective trans- 5-7 highest subsequent retrospective anti- prospective perinatal child-bearing less female female military highest northern drug-abusing asymptomatic hemoph- seropositive geographic coincidental high heterosexual major central symptomatic similar poor T-lymphocyte humoral less uncommon pneumococcal age-matched consistent defective humoral HTLV-III/LAV-infected measles-mumps-rubella protective 5-66 severe normal immunologic individual severe asymptomatic more intact symptomatic small prospective symptomatic immunologic 5-13 asymptomatic immunologic symptomatic live immunodefi- serious adverse symptomatic theoretical antigenic inactivated clinical child- symptomatic HTLV-III/LAV-infected abnormal pri- secondary asymptomatic symptomatic HTLV-11I/LAV-infected in- Other abnormal immuno- logic asymptomatic HTLV-111/LAV-infected 30-month follow-up immune oral Immune-deficient higher vaccine-associated normal 20-22 potential HTLV-III/LAV-infected local child- high HTLV-III/LAV-infected high fatal tsuch sexual HTLV-111/LAV-infected parenteral expo- perinatal routine medical symptomatic perinatal im- possible vaccine-associated adverse seventy-one re- least pri- mary available consistent least live-virus serious unusual adverse medical adverse HTLV-III/LAV-infected 19-year-old asymptomatic basic primary small- one-half cryptococcal treat- vaccine-associated HTLV-III/LAV-infected other serious ad- pediatric asymptomatic pre- necessary knowledgeable little available special symptomatic live-bacterial young other clinical routine medical regula- indi- such other inactivated potential theoretical adverse effective immunocompetent 28-30 other chronic annual one-time pneumococcal 31-33 young other clinical other immunosup- serious infectious such significant passive immune immune asymptomatic small young overt clinical manifesta- live-virus available such 20-22 possible adverse vaccine-preventable effective uninfected Available adverse overt clinical such due spread prudent asymptomatic recom- full intravenous 2-4 other clinical such young due other immunosuppressed routine extensive ex- vaccinated 20-22 255:2299-2305 clirical epidemiologic public perinatal human /lymphadenopathy-associated symptomatic asymptomatic 253:363-6 human cial 2:581-5 general healthy immunodeficier.cy III/lymphadenopathy-associated military 35:421-4 immune 60:85-90 humoral pediatric immune deficien- 107:352-7 cell-mediated pediatric AIDS-related natural lymphadenopathy-associated human 32:1-8 13-17 immune pneumococcal 1174-6 Paralytic 31:617-20 1210-31 live retro- spective sexual alic abuse-related human III/lymphadenopathy-associated 35:152-5 other preventive 34:201-5 pneumococcal usage 33:273-6 35:317-26 1986-1987 35:517-21 33:84-90 95-100 / 197-200 certain certain certain follow oral available permanent medical permanent health-care private public federal local applicable additional federal local present adverse local health-care adverse local available Reportable anaphylactic hypotonic- hyporesponsive acute additional such anaphylactic acute additional non-immunodeficient vaccine-associated additional anaphylactic additional Shock-collapse hypotonic-hyporesponsive such partial complete pale white unresponsiveness environmental other less first mumps- other more grand myoclonic tonic-clonic focal significant frequent focal neurologic intracranial least neurologic temporary complete various permanent such high-pitched unusual unconsolable compatible conclusive encepha- slow Reportable health-care other personal Such local personal manu- local manu- such / 663-664 669-675 last additional educational serious primary 1-4 negative isoniazid preventive continuous active continuous high annual new other high human bacterial susceptible infectious derivative clinical certain younger older cell-mediated diagnosed least other compatible abnormal physical positive clinical extrapulmonary difficult spinal few nationwide lower higher pulmonary previous 28:241-4 fatal recent final available different high most racial/ethnic high pulmonary racial/ethnic foreign-born active difficult active symptomatic 100-200 greater general asymptomatic high clinical racial/ethnic fourth extrapulmonary miliary miliary stable occupational same general high-risk new negative positive recent health-care highest health-care community-acquired nontuberculous occupational general important early infectious noncontagious few case-finding clinical public noncontagious such extrapulmonary pulmonary tuberculous infectious clinical such new low infectious potential numerous difficult high chest clinic effective unavoidable other feasible serial available original cultural genetic bacterial environ- freeze-dried various available large south freeze-dried different sputum-positive reliable precise observational historical cross-sectional such tuberculous lower pulmonary lower unvaccinated observational serious same greater impaired tuberculous accelerated normal skin nutritional possible mycobacterial differential infectious several high positive high infectious high positive recent general low tuberculous high-risk modern most periodic high-risk preventive negative positive tuberculin-positive infectious other high-risk tuberculin-positive entire uninfected high continuous infectious undetected untreated skin-test-negative recom- negative high untreated infectious pulmonary long-term resistant excessive new tuberculin-negative new usual feasible regular usual unacceptable accessible health-care high new health-care adequate isoniazid preventive skin-test-positive high recent medical such renal health-care available available available negative old usual congenital generalized high symptomatic asymptomatic asymptomatic greater inconclusive high asymptomatic possible symptomatic low harmful adverse ten-year general protective final urban 101:481-5 36:133-5 five-year large serial two-step serial serial tuberculous urban methodological statistical Fifteen-year Indian neonatal Canadian 14:441-6 skin African 18-month Indian human avian 5-year prospective protective mycobacterial 253:3438-9 perinatal prognostic joint human routine 617-624 endemic epidemic southern southeastern epidemic much certain rare usual itinerary endemic effective clinical cholera-infected longer cholera-infected sufficient available phenol-inactivated classic such unlikely long-term such ship international low most standard many other enteric many such epidemic complete primary complete primary special high-risk sanitary local many acceptable many private valid previous yellow 1-3 lower-titered unaffected clinical unknown yellow least possible 3-week yellow least intradermal necessary endemic unsanitary primary effective 1-2 local serious unvaccinated medical such unvaccinated specific actual intramuscular mos-4 5-10 old subcutaneous intramuscular 1977:1-12 international une 126:231-46 intradermal subcutaneous previous 34:341-2 current infor- other high-risk effective global last free importa- routine active general civilian several military military international possible nonvariola microbio- logical biomedical recommen- animal-care orthopox- recombinant clinical infectious percutaneous second epidemiologic primary-type double-stranded broad experimental many different pathogenic low foreign Such foreign infectious human 16-21 several neuroadapted available / more pathogenic reliable animal particular Laboratory-acquired human other health-care clinical recombinant health-care unknown health-care appropriate infection- less laboratory smaller lower clinical such health-care direct other infectious clinical other health-care viral other infective appropriate other Other such limited lower laboratory theoretical low percutaneous low uncontrolled unusual large higher unknown foreign available other percutaneous admin- non-immune primary vesicular maximum typical regional 2-4 viral 4-14 common more primary common unpublished Erythematous urticarial bullous other frequent Table common nose specific immune useful ocular vesicular limited little serious severe progressive postvaccinial least primary older systemic other / severe fatal serious primary independent severe fatal progressive metastatic cellular serious primary neurologic rare primary postvaccinial susceptible 10-state total several military single uncomplicated inadvertent inocula- severe < 5-19 local bacterial simultaneous multiple several postvaccinial enceph- careful Special present other chronic pregnant rare occa- primary fetal fetal large such such severe least severe asymptomatic HIV-infected military multiple recent HIV-infected autologous recombinant present smallpox RR-14 HIV-related additional available prudent neomycin anaphylactic porous occlusive dry impermeable health-care good Semipermeable effective viral dry important other available sterile effective progressive useful ocular severe serious early possible therapeutic large 24- new other human orthopox- severe other health-care occu- other orthopox- responsible 639-3670 available RR-14 800-822-7967 local global available civilians-United 29:417-20 microbiological biomed- ical available at-risk percutaneous cutaneous plaque El-Ad revaccina- percutaneous percutaneous infectious vaccinia-naive immunological 337:567-72 live Laboratory-associated hospital microbiological biomed- ical vaccinia-naive tional smallpox 281:1201-7 22:251-72 50:22-42 military smallpox vaccination-Michigan previous yellow necessary special immunosup- pregnant simultaneous other yellow fever- urban distinguishable identical yellow epidemic viral susceptible domestic close urban early last documented aegypti-borne yellow western recent Other enzootic yellow aegypti-transmitted human rural enzootic viral various mosquito forest-savannah tropical 100-300 occupational underreported tree-hole-breeding few few animal prompt human yellow active unrecognized yellow endemic human yellow safe effective chick freeze-dried 1-dose 5-dose domestic frozen unused yellow 1980-1987 endemic yellow available local available urban yellow actual recent fatal rural yellow endemic pregnant epidemic yellow high feasible yellow direct indirect international international yellow different Yellow territorial nonfederal local international other current international up-to-date valid Such single subcutaneous several 8-10 yellow least 30-35 yellow low-grade other minor 5-10 regular uncommon susceptible serious adverse older age-related possible available adverse pregnant yellow international pregnant yellow small theoretical yellow theoretical other human Such yellow fever-infected necessary short-term < intra-articular immunosuppressive yellow asymptomatic possible adverse such effective non-HIV-infected such appropriate yellow able international patient acceptable letterhead stationary specific authoritative questionable essential high intradermal medical other simulta- possible certain other various few yellow full yellow other live live sequential yellow 1-3 lower normal yellow minimal least 3-week yellow possible yellow Japanese prospective available immune immunologic yellow Yellow western arthropod-borne human yellow 11:570-5 international haemagglutination-inhibiting 27:669-707 30-35 yellow 59:895-900 arthropod-borne yellow yellow 12:230-5 live yellow 126:363-71 yellow 1:457-8 66:258-66 trivalent oral yellow 62:585-90 previous 27:231-3 oral live-attenuated available previous recommen- low other available civilian oral live-attenuated Swiss parenteral heat-phenol-inactivated many Chilean laboratory-confirmed least interval subsequent significant clinical unknown humoral viable primary heat-phenol-inactivated similar available parenteral acetone-inactivated parenteral available Parenteral heat-phenol-inactivated oral live-attenuated live-attenuated similar heat- phenol-inactivated fewer adverse endemic endemic-disease parenteral small effective typhoid greatest Such typhoid careful effective large such continued endemic useful common-source rural natural such typhoid • live-attenuated enteric-coated maximum inactivated • live-attenuated enteric-coated maximum inactivated parenteral common parenteral weekly effective parenteral parenteral single parenteral sufficient heat-phenol-inactivated intradermal subcutaneous acetone-inactivated severe local oral live-attenuated primary parenteral reasonable parenteral similar adverse unavailable adverse optimal longest follow-up entire available oral live-attenuated enteric-coated rare abdominal adverse equal several systemic local severe local severe acetone-inactivated greater local parenteral severe local systemic previous oral live-attenuated pregnant Live-attenuated immunocompromised human alternative international 283:686-91,739-46 typhoid 1975-1984 foreign 11:1-8 international 148:599-602 ii:1056-60 serologic acetone-inactivated typhoid heat-killed 51:501-5 typhoid 34:321-39 Polish 1961-1964 acetone-dried inactivated heat-phenol-inactivated 30:623-30 Oral Live-Attenuated UDP-glucose-4-epimeraseless live oral live oral enteric-coated endemic 159:766-9 live oral enteric-coated i:1049-52 live oral / RR-3 1-19 Other previous 33:393-402,407-8 current domestic fewer fewer human human domestic many possible frequent domestic wild animal continental rabies-free important potential domestic most major major human rare receive additional available systemic prophylactic occasional severe 10-14 active passive human many local passive effective 15-20 active 7-10 rapid passive short local local unavailable 639-2888 prophy- human single-dose vial 800-VACCINE final single-dose human cell-derived available fetal 26-32 available efficacious safe full 1.0-ml 33-36 human international 2-ml 10-ml pediatric efficacious safe possible necessary local public specific open mucous necessary nonbite highest open mucous other infectious such animal noninfectious Other such urine occasional such sufficient highest large aerosolized airborne probable airborne bat-infested compatible 40-43 such respiratory airborne animal public available geographic free negative other public other 10-day first symptomatic possible negative wild indigenous human possible continental free available subsequent carnivorous such unnecessary negative immunoflu- valuable small public Such such local domestic wild wild susceptible unknown wild domestic continental enzootic mid-Atlantic large rabies-infected fewer fewer enzootic healthy domestic veterinarian local most major such special aware main animal rabies-enzootic high such healthy 10-day unprovoked domestic likely healthy rare single essential local Table many 90-day safe effective proven excellent 28-day safe feasible same same anatomical active more deltoid applicable acceptable older younger previous other prior important simple local large cosmetic available 1-ml first five-dose possible anterolateral acceptable passive complete other local systemic satisfactory routine unusual immediate seventh applicable feasible same same anatomical active more various last 2-4 necessary 2-4 rapid equivalent minimum primary three-dose three-dose continuous primary continuous local serologic endemic present high mucous nonbite acceptable unrecognized diagnostic mucous enzootic foreign nonbite greater episodic large low nonbite large necessary large epizootic relative extra acceptable complete necessary additional local such vaccine active various newer culture-derived such efficacious 0.1-ml different suprascapular thigh abdominal 0.1-ml efficacious 0.1-ml different 0.1-ml active 2-1-1 1.0-ml 63-65 available adverse low most minor 66-68 additional other culture-derived 69-71 other antiviral gluteal passive such veterinar- certain foreign endemic Other frequent other several inapparent Second additional particular available high adverse 1.0-ml Other comparable 0.1-ml Table 1.0-ml single 0.1-ml lateral upper primary 0.1-ml 1.0-ml multi-dose malaria-endemic sufficient rabies-enzootic least full three-dose antimalarial possible other prudent similar continuous highest Such least complete other such diagnostic animal- epizootic international endemic complete low unnecessary satisfactory serologic necessary live licensed vaccine-induced best low vaccine-associated frequent expo- available high associated needle true periodic animal serious common available three-dose local such such abdominal neurologic few other subacute central peripheral nervous immune complex-like 2-21 life-threatening primary betapropiolactone-altered human primary Other neuroparalytic low-grade angioneurotic nephrotic clear human other available local systemic adverse such anti-inflammatory antipyretic serious available anaphylactic serious systemic anaphylactic neuroparalytic such serious serious adverse serious neuroparalytic anaphylactic other immunosuppressive immunosuppressive active such immune inadequate other other immunosuppressive important acceptable fetal substantial serious Reid-Sanden 197:1571-83 human 1980-1981 1990-6 34:700,705-7 34:235-6 37:305-8 38:335-7 33:469-70 human 32:78-80,85-6 30:537-40 human 248:3136-8 allergic human 33:185-7 complex-like human 4:45-9 human intradermal human 3:96-101 human 142:133-8 new human 236:2751-4 clinical new human human 40:3-9 human human 6:211-9 homologous heterologous 102:1314-21 human non-exposed purified 131:799-805 supplementary human intradermal 35:767-8 human lower 34:90-2 new 37:217-8,223 diploid new 152:204-10 diploid neurological 4:225-7 diploid new clinical prophylactic 249:2663-5 diploid new initial clinical 247:1726-8 three-dose pre-exposure human two-year 137:783-8 small subcutaneous 247:1138-42 intradermal human primary 257:1059-63 human dose-response 156:50-5 non-bite 135:142-8 226:1219-21 26:183-4 30:473-4 corneal 29:25-6 300:603-4 animal 196:36-9 1971-1984 mid-Atlantic 22:151-5 37:559-60 clinical 197:201-9 local 28:477-86 local 26:765-75 human diploid-cell 318:124-5 clinical human 10:357-67 present clinical Asian 19:549-61 human 37:273-86 intradermal 31:279-80,285 side primary pre-exposure Washing- 335:1201-5 intradermal human diploid-cell-strain effective intradermal 335:896-8 human diploid 113:270-5 second four-vaccine comparative 2-1-1 4:245-8 human 6:489-90 human 2-1-1 6:283-6 safe affordable human human vaccine- 36:759-60,765 appropriate post-exposure 316:1257-8 7:49-52 human final human 27:553-61 33:393-402,407-8 human diploid-cell 314:280-4 Pre-exposure human early human 35:663-70 human 12:231-2 1:1334-5 specific human human urticarial 143:717-8 / Japanese Japanese available investigational collabo- Japanese military Japanese mosquito-borne arboviral viral 2-4 sporadic epidemic Indian severe fatal out- residual first second preg- intrauterine third adverse enzootic vertebrate- domestic principal prevalent rural human vertebrate-amplifying agricultural activi- urban temperate re- early subtropical tropical seasonal viral verte- brate-amplifying avian-amplifying tropical agricultural important viral individual endemic annual universal asymptomatic susceptible Japanese endemic viral Japanese second applicable widespread northern sporadic endemic year-round endemic hyperendemic endemic hyperendemic new second Irian other major Last major 1982-1983 available occasional endemic- hyperendemic wide seasonal Most Japanese southern southern Southern southern endemic epidemic temperate central June-January endemic year-round greatest April-January eastern mountainous secondary central epidemic northern enzootic northwestern central sporadic island-wide north sporadic sporadic zootic sustainable September-January high local incidental human personal available secondary biological other low individual such rural principal outdoor protective air-condi- well-screened additional natural susceptible elderly susceptible neuroinvasive viral rural endemic few rural 2-week military Table obser- additional other western Japanese available outbound un- low short-term urban available limited high rural endemic resident annual in- 5-month 1-month Similar < 0.1-2.1 non-immunized Western military 18-23 likely neuroinvasive protective outdoor twilight other protamine ul- further sucrose several basic refer- clinical single placebo-controlled ad- / overall brain-derived re- single unvaccinated single single ble protective immunized natural efficacious primary many adminis- 1-4 British protective suitable reciprocal 6-12 Asian prior other universal early Japanese virus western 146-214 n British 31-61 short three-dose p flaviviral most flaviviral inactivated tick-borne en- previous flaviviral such unpublished immunogenic 30-day geometric higher longer unpublished unchanged primary neu- primary Japanese moderate local systemic other local other such abdominal neural vaccine-related neurologic vac- encephalitogenic vaccine-related neurologic encephalopathy sei- positive unpublished other new adverse unpublished personal oro- / dis- other several Most an- oral parenteral objective immu- nologic important first second median second third second third similar first second unpublished military envenoma- physical other idiopathic relative unpublished adverse active military sudden 21-year-old first third medical epi- possible dead adverse Table 50-104 10-fold lower adverse new unclear such adverse vac- adverse Other similar clinical similar adverse anaphylactic other responsible adverse adverse similar adverse other re- certain uncertain Post-marketing Japanese 4-13 0.3-9.6 0.2-7.2 1.7-16 .02-3.7 0.13-29 3-30 10-140 2.6-567 1.8-54 0.5-105 military 54-71 additional additional unknown total exercise-induced available / endemic epidemic 40-44 ac- variable endemic unexpected high-risk general endemic trans- rural specific en- demic such extensive rural high personal other alternative protective available incom- endemic short- reactogenic serious low symptomatic fetal special per- pregnant endemic primary ad- impractical inconvenient short-term unusual last least adequate medical ad- identical able least three-dose primary full unknown definitive other available ready medical certain allergic greater adverse indi- such prophylactic prevent- vaccine-related allergic neural other rodent neural experimental hantaviral vac- French yellow previous ad- allergic unusual adverse 1-800-822-7967 available possible specific available Vacci- unknown theoretical high theoretical altered small adverse Other simultaneous unpub- other im- laboratory-acquired other accidental expo- percutaneous con- viral mucous central nervous olfactory vaccine-derived such unknown labora- potential infectious vaccine-related Japanese Japanese current epidemiological Japanese 1990:763-814 pediatric infectious third 1992:1468-75 Transplacental Japanese encepha- Japanese Indian Asian 20:559-73 arthropod-borne natural Japanese Japanese Southeast Asian Japanese nese Japanese two-week 150:334-6 Japanese 6:261-5 inac- Japanese Communicable arthropod-borne other American Japanese general infectious Japanese 2:317-329 Recent Japanese Japanese vac- Asian 20:653-4 Japanese Indian live-attenuated Japanese Japanese second mouse-brain Japanese Immu- Japanese 1972:285-91 Japanese sub- Japanese yellow improved Japanese nonendemic Further Japanese vac- Japanese adverse 17-32:173–7 encephalo- Japanese Japanese / Japanese Japanese 338:881-2 Japanese 1:853-4 Japanese international 86-8 younger Arboviral general 3:62-9 Japanese underlying microbiological biomedical 02-013-01 